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Role	  of	  ethanol	  metabolites	  in	  its	  central	  eﬀects	  
Acquas	  Elio1,	  Michela	  Rosas1,	  Liliana	  Spina1,	  Alessandra	  Peana2,	  Ezio	  Carboni3,	  Pierluigi	  Caboni1	  and	  	  Miriam	  Melis3	  
1Department	  of	  Life	  and	  Environmental	  Sciences,	  University	  of	  Cagliari	  2Department	  of	  Chemistry	  and	  Pharmacy,	  University	  of	  Sassari	  
3Department	  of	  Biomedical	  Sciences,	  University	  of	  Cagliari	  
The	  role	  of	  acetaldehyde,	  the	  ﬁrst	  metabolite	  of	  ethanol,	  in	  the	  eﬀects	  of	  its	  parent	  compound	  has	  gone	  a	  profound	  re-­‐evaluaJon	  in	  the	  last	  ﬁve	  
decades	  since	  the	  descripJon	  made	  in	  the	  early	  50's	  that	  paJents	  treated	  with	  the	  aldehyde	  dehydrogenase	  inhibitor,	  antabuse,	  could	  perceive	  
more	  pleasurable	  eﬀects	  when	  drinking	  small	  volumes	  of	  alcoholic	  beverages.	  However,	  the	  suggesJon	  that	  acetaldehyde	  could	  be	  a	  mediator	  
of	   some	   of	   the	   eﬀects	   of	   ethanol	   did	   never	   defeat	   the	   scepJcism	   of	   the	   scienJﬁc	   community	   on	   the	   “acetaldehyde	   hypothesis”	   unJl	   the	  
discovery	  of	  catalase,	   the	  enzyme	  that	  converts	  ethanol	   into	  acetaldehyde	  within	  the	  brain.	  Since	  then	   it	  has	  been	  demonstrated	  that	  either	  
ethanol-­‐derived	   acetaldehyde	   and	   acetaldehyde,	   on	   its	   own,	   share	   some	   criJcal	   behavioural	   and	   neurochemical	   features	   of	   its	   parent	  
compound.	  	  
In	  this	  scenario	  the	  aim	  of	  our	  studies	  was	  to	  further	  invesJgate	  the	  role	  of	  acetaldehyde	  and	  of	  the	  acetaldehyde-­‐dopamine	  (DA)	  conjugate,	  
salsolinol,	  in	  the	  eﬀects	  of	  ethanol	  by	  assessing	  1)	  the	  ability	  of	  acetaldehyde	  to	  elicit	  Extracellular	  Signal	  regulated	  Kinases	  (pERK)	  in	  nuclei	  of	  
the	  extended	  amygdala	  by	   immunohistochemistry	  experiments;	  2)	  the	  role	  of	  pERK	  as	  well	  as	  of	  DA	  and	  opioid	  receptors	   in	  the	  moJvaJonal	  
eﬀects	   of	   acetaldehyde	   as	   determined	   by	   condiJoned	   place	   preference	   (CPP)	   and	   self-­‐administraJon	   (SA)	   experiments;	   3)	   the	   role	   of	  
acetaldehyde,	  catalase	  and	  salsolinol	  in	  the	  ability	  of	  ethanol	  to	  excite	  dopamine	  neurons	  in	  the	  posterior	  ventral	  tegmental	  area	  (pVTA)	  by	  ex	  
vivo	  electrophysiology.	  
The	   results	   of	   these	   studies	   demonstrate	   that	   (1)	   in	   the	   immunohistochemistry	   experiments	   acetaldehyde	   (10	   and	   20	   mg/kg),	   similarly	   to	  
ethanol	  (1	  g/kg),	  elicits	  pERK	  in	  the	  nucleus	  accumbens	  and	  other	  nuclei	  of	  the	  extended	  amygdala	  in	  a	  DA	  D1-­‐dependent	  manner.	  In	  addiJon,	  
the	  eﬀects	  of	  ethanol	  on	  pERK	  expression	  are	  prevented	  by	  blockade	  of	  peripheral	  metabolism	  of	  ethanol	  with	  4-­‐Methylpyrazole	  (90	  mg/kg)	  and	  
by	  acetaldehyde	  sequestraJon	  with	  D-­‐penicillamine	   (50mg/kg).	  The	  results	  also	  show	  (2)	   that	  acetaldehyde	   (20	  mg/kg)	  elicits	  CPP	  and	  this	   is	  
prevented	   by	   either	   blockade	   of	   DA	   D1	   receptors	   and	   of	   Mitogen-­‐acJvaJng	   Extracellular	   Kinase	   (MEK),	   the	   kinase	   responsible	   of	   ERK	  
phosphorylaJon.	   In	  addiJon,	  the	  SA	  experiments	  conﬁrmed	  that	  acetaldehyde	  (0.2%)	   is	  self-­‐administered	  orally	  and	  that,	  similarly	  to	  ethanol	  
oral	   SA,	   also	   acetaldehyde	   SA	   is	   subjected	   to	   an	   opioid	   receptor	  mediated	   control	   since	   naltrexone	   (0.4-­‐0.8	  mg/kg)	   prevents	   its	   acquisiJon,	  
maintenance	  and	  deprivaJon	  eﬀect.	  Finally,	  (3)	  the	  electrophysiological	  experiments	  brought	  to	  the	  demonstraJon	  that	   in	  order	  to	  excite	  DA	  
neurons	  in	  the	  pVTA	  it	  is	  necessary	  that	  a	  two-­‐step	  sequenJal	  mechanism	  takes	  place:	  a)	  conversion	  of	  ethanol	  into	  acetaldehyde	  by	  the	  acJon	  
of	  catalase	  and	  b)	  condensaJon	  of	  acetaldehyde	  with	  DA	  to	  produce	  salsolinol.	  Overall	  these	  results	  provide	  evidence	  in	  further	  support	  of	  the	  
view	  that	  the	  metabolism	  of	  ethanol	  plays	  a	  key	  role	  in	  some	  of	  its	  central	  eﬀects	  and	  strongly	  suggest	  that	  this	  holds	  true	  also	  for	  its	  ability	  to	  
excite	  DA	  neurons.	  
	  
L-­‐DOPA	  inhibits	  cue-­‐induced	  reinstatement	  of	  cocaine-­‐seeking	  behavior	  without	  altering	  cocaine-­‐intake	  in	  rats	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  Silvia1,	  Fadore	  Liana2,3,	  Frada	  Walter1,2,	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  Luigi1,2,	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1Department	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We	   have	   recently	   shown	   that	   systemic	   administraJon	   of	   the	   dopamine-­‐beta-­‐hydroxylase	   inhibitors	   disulﬁram	   and	   nepicastat	   suppresses	  
cocaine-­‐induced	  reinstatement	  of	  cocaine-­‐seeking	  behavior	  in	  rats,	  and	  contextually	  increases	  cocaine-­‐induced	  dopamine	  release	  in	  the	  medial	  
prefrontal	   cortex	   (mPFC).	   The	  behavioral	   eﬀects	   are	  mediated	  by	   a	   supra-­‐maximal	   sJmulaJon	  of	  dopamine	  D1	   receptors	   that	   leads	   to	   their	  
funcJonal	  inacJvaJon.	  Similarly,	  L-­‐DOPA	  administraJon	  was	  demonstrated	  to	  suppress	  cocaine-­‐induced	  reinstatement	  (Devoto	  et	  al.,	  2014).	  
In	  this	  follow-­‐up	  study	  we	  veriﬁed	  whether	  the	  suppressant	  eﬀect	  of	  L-­‐DOPA	  on	  cue-­‐induced	  reinstatement	  of	  cocaine-­‐seeking	  behavior	  was	  as	  
eﬀecJve	   as	   on	   drug-­‐induced	   reinstatement.	   To	   this	   aim,	   male	   rats	   were	   trained	   to	   daily	   self-­‐administer	   cocaine	   (0.5	   mg/kg/infusion)	  
intravenously	  for	  2	  hours	  under	  a	  ﬁxed	  raJo	  1	  schedule	  of	  reinforcement,	  each	  cocaine	  infusion	  being	  associated	  with	  visual	  (light)	  and	  auditory	  
(noise)	  cues.	  SJmuli	  associated	  with	  drug	  intake	  play	  a	  key	  role	  in	  relapse	  to	  drug-­‐seeking	  in	  humans.	  Thus,	  ager	  a	  prolonged	  exJncJon	  training,	  
animals	  underwent	  cue-­‐induced	  reinstatement	  test	  sessions.	  Acute	  exposure	  to	  a	  cue	  priming	  immediately	  before	  starJng	  the	  session	  promptly	  
reinstated	  drug-­‐seeking	  behavior	  to	  the	  pre-­‐exJncJon	  responding	  level.	  This	  eﬀect	  was	  eﬃcaciously	  reversed	  by	  pretreatment	  with	  L-­‐DOPA	  at	  
the	  same	  dose	  (50	  mg/kg)	  previously	  shown	  to	  be	  eﬀecJve	  in	  prevenJng	  cocaine-­‐induced	  reinstatement.	  
Extended	  access	  to	  self-­‐administered	  cocaine	  may	  produce	  a	  number	  of	  symptoms	  characterisJc	  of	  addicJon	  that	  are	  not	  seen	  following	  more	  
limited	  drug	  access,	  including	  persistent	  cogniJve	  deﬁcits	  (Paterson	  and	  Markou,	  2003).	  Thus,	  the	  next	  step	  of	  our	  study	  was	  to	  allow	  animals	  to	  
resume	   responding	   for	   cocaine	   during	   extended	   (6	   hours)	   daily	   sessions	   for	   1	  week.	   As	   expected,	   cocaine	   self-­‐administraJon	  was	   promptly	  
reacquired	  and	  the	  mean	  number	  of	  acJve	  lever-­‐presses/hour	  was	  roughly	  similar	  between	  the	  2-­‐	  and	  the	  6-­‐hours	  self-­‐administraJon	  sessions	  
(14.84	  and	  10.73).	  Once	  cocaine	  self-­‐administraJon	  behaviour	  was	  stably	  re-­‐acquired,	  rats	  were	  pretreated	  with	  L-­‐DOPA	  either	  on	  the	  last	  day	  
of	  cocaine	  self-­‐administraJon	  training	  or	  during	  cue-­‐induced	  reinstatement	  of	  drug-­‐seeking	  behavior.	  Results	  showed	  that	  L-­‐DOPA	  did	  not	  aﬀect	  
cocaine	  intake	  but	  was	  able	  to	  prevent	  cocaine-­‐seeking	  reinstatement	  induced	  by	  re-­‐exposure	  to	  an	  acute	  cue	  priming.	  
Overall,	  our	  ﬁndings	  showed	  that	  even	  though	  L-­‐DOPA	  does	  not	  aﬀect	  voluntarily	  cocaine	  intake	  in	  rats,	  it	  may	  be	  useful	  in	  the	  suppression	  of	  
relapse	  to	  cocaine	  seeking	  since	  it	  is	  able	  to	  prevent	  both	  drug-­‐	  and	  cue-­‐induced	  reinstatement	  of	  cocaine-­‐seeking.	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The	  hypoacJvity	  of	   the	  mesolimbic	  dopamine	  (DA)	  system	  arising	   from	  the	  ventral	   tegmental	  area	   (VTA)	  has	  been	   implicated	   in	   the	  aversive	  
consequences	   of	   withdrawal	   from	   several	   drugs	   of	   abuse	   including	   Cannabis	   [Diana	   et	   al.,	   1998].	   These	   neuronal	   adaptaJons,	   which	   are	  
characterized	  by	  imbalances	  between	  excitatory	  and	  inhibitory	  aﬀerents	  onto	  DA	  cells,	  are	  thought	  to	  underlay	  the	  withdrawal-­‐induced	  negaJve	  
aﬀecJve	  states	  that	  eventually	  lead	  to	  relapse	  into	  drug	  taking.	  The	  rostromedial	  tegmental	  nucleus	  (RMTg),	  a	  GABA	  structure	  which	  receives	  a	  
strong	   input	   from	   the	   lateral	   habenula	   (LHb)	   and	   projects	   densely	   to	   midbrain	   DA	   neurons,	   is	   an	   important	   site	   involved	   in	   aversion	   and	  
appeJJve	  processes.	  In	  fact,	  both	  RMTg	  and	  LHb	  cells	  are	  acJvated	  by	  aversive/unpleasant	  events	  and	  inhibited	  by	  rewarding/posiJve	  sJmuli.	  
RMTg	  GABA	  neurons	  exert	  a	  negaJve	  control	  over	   the	  VTA,	  express	  CB1	   receptors	  on	   their	  axon	   terminals	   impinging	  upon	  VTA	  DA	  neurons	  
[Melis	  et	  al.,	  2014],	  and	  are	  a	  target	  for	  cannabinoid	  acJon	  on	  DA	  cells.	  Indeed,	  acute	  exposure	  to	  these	  drugs	  reduces	  RMTg	  neuron	  discharge	  
acJvity	   and	   strongly	   suppresses	   the	   inhibiJon	   exerted	   by	   RMTg	   aﬀerents,	   thus	   contribuJng	   to	   cannabinoid-­‐induced	   DA	   neuronal	   excitaJon	  
[Lecca	  et	  al.,	  2011;	  Lecca	  et	  al.,	  2012].	  
On	  these	  bases,	  we	  hypothesized	  that	  RMTg	  GABA	  projecJons	  to	  VTA	  might	  be	  causally	  involved	  in	  the	  hypodopaminergic	  state,	  which	  is	  one	  
hallmark	  of	  cannabinoid	  withdrawal.	  	  
To	  address	  this	   issue,	  we	  used	  single	  unit	  extracellular	  recordings	  from	  RMTg	  and	  VTA	  neurons	  in	  anestheJzed	  male	  Sprague-­‐Dawley	  rats.	  To	  
induce	  Δ9-­‐tetrahydrocannabinol	  (Δ9-­‐THC)	  dependence,	  rats	  were	  chronically	  treated	  with	  it	  (15	  mg/kg,	  i.p.),	  or	  its	  vehicle,	  twice	  daily	  for	  6.5	  days	  
[Diana	   et	   al.,	   1998].	   AdministraJon	   of	   the	   cannabinoid	   antagonist	   rimonabant	   (5	  mg/kg,	   i.p.)	   precipitated	   an	   intense	   behavioral	  withdrawal	  
syndrome	  (p<	  0.0001	  versus	  control	  (one-­‐way	  ANOVA	  and	  Dunned's	  test),	  whereas	  abrupt	  Δ9-­‐THC	  suspension	  caused	  milder	  signs	  of	  absJnence	  
(p<	  0.01	  versus	  control	  (one-­‐way	  ANOVA	  and	  Dunned's	  test)).	  Electrophysiological	  experiments	  conﬁrmed	  that	  Δ9-­‐THC	  withdrawal	  produced	  a	  
marked	   decrease	   in	   the	   ﬁring	   rate	   and	   burst	   ﬁring	   of	   VTA	   DA	   neurons	   (p<	   0.01	   versus	   control	   (one-­‐way	   ANOVA	   and	   Dunned's	   test)).	   As	  
expected,	  RMTg	  sJmulaJon	  elicited	  a	  complete	  suppression	  of	  DA	  neuron	  discharge	  acJvity.	  Remarkably,	  in	  Δ9-­‐THC	  withdrawn	  rats	  the	  duraJon	  
of	  RMTg-­‐evoked	  inhibiJon	  was	  prolonged	  when	  compared	  with	  controls,	  suggesJng	  an	  augmented	  GABA	  inhibitory	  input	  onto	  DA	  cells.	  On	  the	  
other	  hand,	  the	  spontaneous	  acJvity	  of	  RMTg	  GABA	  neurons	  was	  reduced	  in	  cannabinoid-­‐withdrawn	  rats.	  Given	  the	  anatomical	  and	  funcJonal	  
role	  of	  the	  LHb,	  we	  are	  currently	  invesJgaJng	  whether	  LHb	  neuronal	  ﬁring	  is	  altered	  ager	  cannabinoid	  withdrawal.	  
Our	   ﬁndings	   support	   the	   idea	   that	   enhanced	   GABA	   output	   from	   RMTg	  might	   contribute	   to	   the	   hypodopaminergia	   induced	   by	   cannabinoid	  
withdrawal,	  and	  conﬁrm	  that	  the	  RMTg	  takes	  part	  in	  the	  neuronal	  circuits	  underlying	  drug	  dependence	  and	  addicJon.	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Cocaine-­‐related	  disorders	  are	  currently	  among	  the	  most	  devastaJng	  mental	  disease	  as	  they	   leads	  to	  profound	  disturbances	   in	  an	   individual’s	  
behaviour	   resulJng	   in	   tremendous	   economic,	   social,	   and	  moral	   costs.	   Imaging	   studies	   in	   human	   have	   shown	   a	   reducJon	   of	   dopamine	   (DA)	  
receptors	  accompanied	  by	  a	  lesser	  release	  of	  endogenous	  DA	  in	  the	  ventral	  striatum	  (AVT)	  of	  cocaine	  subjects	  thereby	  resulJng	  in	  a	  ‘dopamine-­‐
impoverished’	  brain1-­‐2.	  This	  perturbaJons	  lead	  to	  neuroadpataJons	  in	  several	  other	  circuits	  which	  are	  related	  to	  moJvaJon,	  inhibitory	  control,	  
and	  memory	  which	   ﬁnally	   determ	   compulsive-­‐impulsive	   self	   drug	   administraJon3.	   The	   lasJng	   reducJon	   in	   	   physiological	   acJvity	   of	   the	   DA	  
system	   leads	   to	   the	   idea	   that	  an	   increment	  on	   its	  acJvity,	   to	   restore	  pre-­‐drug	   levels,	  may	  yield	   signiﬁcant	  clinical	   improvements2.	  There	   is	  a	  
substanJal	   need	   for	   therapeuJc	   tools	   in	   addicJve	   states	   and	   TMS	   appears	   to	   be	   a	   promising	   ‘non-­‐pharmacologic’	   candidate,	   since	   it	   can	  
modulate	  the	  DA	  system	  and	  the	  funcJon	  of	  related	  areas4.	  It	  has	  been	  just	  reported5	  that	  rTMS	  over	  the	  leg	  dorso-­‐lateral	  prefrontal	  corJces	  
(DLPfcx)	  temporarily	  reduces	  the	  craving	  for	  cocaine	  in	  cocaine	  addicts	  but	  there	  are	  no	  studies	  which	  have	  invesJgated	  the	  TMS	  eﬀects	  in	  the	  
cocaine	  intake.	  Considering	  that	  we	  applied	  bilateral	  deep-­‐rTMS	  to	  the	  DLPfcx	  of	  cocaine	  abusers,	  in	  order	  (1)	  to	  evaluate	  the	   	  short/long	  term	  
therapeuJc	   eﬀects	   of	   TMS	   in	   cocaine	   intake	   trough	   hair	   analysis	   during	   the	   Jme	   line	   (T0,T1,T2,T3..	   	   ),	   (2)	   to	   idenJfy	   opJmal	   parameters	   of	  
sJmulaJon	  (1HZ/10HZ),	  (3)	  to	  highlight	  possible	  correlaJon	  between	  cocaine	  intake	  and	  clinical	  parameters.	  
20	  cocaine	  abusers	  have	  been	  recruited	  selected	  on	  the	  DSM-­‐IV	  criteria	  and	  randomly	  assigned	  to	  real	  rTMS	  group	  (100%	  of	  motor	  threshold,	  10	  
HZ/1	  HZ,	  5	  second	  per	  train,	  20	  trains,	  15	  seconds	  of	   inter-­‐sJmulus)	  or	  to	  sham	  sJmulaJon	  one.	   In	  order	  to	   invesJgate	  the	  eﬀect	  of	  TMS	  on	  
cocaine	  dependence	  we	  assessed	  the	  cocaine	  intake	  trough	  hair	  analysis	  before	  (T0)	  and	  ager	  treatment	  (T1)	  and	  every	  3	  months	  for	  the	  follow-­‐
up	  data.	  The	  interim	  analysis	  shows	  that	  all	  subjects	  have	  reduced	  the	  intake	  of	  cocaine	  regardless	  of	  the	  frequency	  (10	  Hz	  or	  sham	  condiJon)	  of	  
the	  sJmulaJon	  protocol	  applied.	  Six	  months	  ager	  the	  treatment	  (T2)	  all	  treated	  subjects	  show	  a	  reducJon	  in	  cocaine	  intake	  with	  no	  disJncJon	  
among	  groups	  (real	  vs	  sham).	  More	  cases	  are	  needed	  in	  1	  Hz	  and	  sham	  condiJons	  to	  “balance”	  the	  groups.	  The	  follow-­‐up	  data,	  however,	  shows	  
a	  strong	  persistence	  of	  the	  eﬀect	  in	  the	  real	  group,	  and	  decidedly	  weaker	  maintenance	  in	  sham.	  We	  hypothesize	  an	  iniJal	  placebo/sham	  eﬀect	  
which	  disappears	  over	  Jme	  in	  the	  sham	  paJents	  group.	  More	  cases	  are	  needed	  in	  1	  hz	  and	  sham	  condiJon	  to	  balance	  the	  groups.	  Nevertheless	  
these	  preliminary	  data	  encourage	  further	  invesJgaJon	  to	  evaluate	  the	  potenJal	  eﬀects	  of	  dTMS	  in	  the	  treatment	  of	  cocaine	  abusers	  and	  in	  the	  
prevenJon	  of	  relapses.	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Environmental	  enrichment	  reverts	  the	  eﬀects	  of	  conBnuous	  or	  intermiMent	  perinatal	  alcohol	  exposure.	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Alcohol	  consumpJon	  during	  perinatal	  periods	  is	  common,	  despite	  the	  warning	  of	  adverse	  eﬀects	  on	  the	  foetal	  development.	  In	  female	  rats,	  the	  
intermident	   padern	   of	   alcohol	   consumpJon	   is	   responsible	   for	   higher	   drinking	   levels	   and	   more	   profound	   disrupJon	   of	   maternal	   care	   than	  
tradiJonal	  conJnuous	  free-­‐access	  paradigm,	  which	  can	  have	  persistent	  eﬀects	  on	  the	  oﬀspring.	  The	  environmental	  enrichment,	  a	  powerful	  form	  
of	   experience-­‐dependent	   plasJcity	   that	   allows	   high	   cogniJve,	   motor	   and	   sensory	   sJmulaJons,	   is	   helpful	   for	   recovering	   from	   diﬀerent	  
neurological	  pathologies.	  	  
Thus,	  this	  study	  aimed	  at	  exploring	  the	  eﬀects	  of	  environmental	  enrichment	  on	  alcohol	  vulnerability	  and	  aﬀecJve	  behaviour	  in	  the	  oﬀspring	  that	  
was	   perinatally	   exposed	   to	   conJnuous	   or	   intermident	   alcohol.	   Dams	   were	   given	   two-­‐bodle	   choice	   to	   water	   and	   20%	   alcohol	   with	   either	  
conJnuous-­‐	  or	   intermident	  access	  (CA	  vs	   IA),	  along	  a	  12-­‐week	  period.	  They	  were	  alcohol-­‐deprived	  during	  breeding	  and	  resumed	  alcohol	  self-­‐
administraJon	  from	  late	  gestaJon	  and	  throughout	  lactaJon.	  Alcohol-­‐exposed	  oﬀspring,	  reared	  in	  either	  standard-­‐	  or	  enriched-­‐	  condiJons,	  were	  
assessed	  for	  alcohol	  drinking	  behaviour	  in	  a	  free-­‐choice	  paradigm	  and	  were	  also	  tested	  for	  the	  deprivaJon	  eﬀect.	  Moreover,	  they	  were	  tested	  
for	  behavioural	  reacJvity	  in	  the	  open	  ﬁeld;	  anxiety-­‐like	  behaviour	  in	  the	  elevated	  plus	  maze	  and	  depressive-­‐like	  behaviour	  in	  the	  forced	  swim	  
test	  during	  the	  drinking	  paradigm.	  
Our	   results	   show	   that	   perinatal	   CA	   to	   alcohol	   did	   not	   increase	   alcohol-­‐drinking	   behaviour	  with	   respect	   to	   controls.	  On	   the	   other	   hand,	   rats	  
perinatally	   exposed	   to	   IA	  displayed	  a	  high	   vulnerability	   to	  alcohol,	   in	   terms	  of	  drinking	  behaviour	   and	  deprivaJon	  eﬀect.	   The	  environmental	  
enrichment	  was	  able	   to	  exert	  a	  protecJve	   role	  on	  alcohol	   vulnerability	   in	  perinatally	   IA	  exposed	   rats	  and	  controls,	  especially	  during	   relapse.	  
Moreover,	  it	  was	  able	  to	  induce	  an	  increase	  in	  behavioural	  reacJvity	  in	  the	  open	  ﬁeld	  and	  a	  decrease	  in	  anxiety-­‐like	  behaviour	  in	  the	  elevated	  
plus	  maze,	  in	  both	  perinatally	  CA	  and	  IA	  exposed	  groups.	  
In	  conclusion,	  the	  padern	  of	  alcohol	  consumpJon	  during	  pregnancy	  and	  lactaJon	  can	  inﬂuence	  long-­‐term	  alcohol	  vulnerability	  in	  the	  oﬀspring.	  
Rearing	  condiJons	  that	  promote	  high	  cogniJve,	  motor	  and	  sensory	  sJmulaJons	  improve	  resilience	  to	  alcohol	  abuse	  and	  aﬀecJve	  tone,	  although	  
they	  cannot	  be	  suﬃcient	  to	  full	  recovery	  from	  detrimental	  eﬀects	  of	  perinatal	  alcohol	  exposure.	  
	  	  
	  	  
Drinking	  paMern	  maMers:	  eﬀects	  on	  maternal	  care	  and	  oﬀspring	  vulnerability	  to	  alcohol	  in	  rats	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Alcohol	  drinking	  during	  pregnancy	  and	  post-­‐partum	  period	  is	  a	  major	  concern	  because	  of	  the	  persistent	  neurobehavioral	  deﬁcits	  in	  the	  oﬀspring,	  
which	  include	  increased	  vulnerability	  to	  substance	  abuse	  (1).	  The	  intermident	  padern	  of	  alcohol	  consumpJon	  induces	  higher	  drinking	  levels	  and	  
deeper	   neurobiological	   changes	   in	   addicJon-­‐related	   brain	   regions,	   with	   respect	   to	   tradiJonal	   free-­‐access	   paradigms	   in	   male	   rats	   (2,	   3).	  
Nevertheless,	  no	  studies	  invesJgated	  on	  the	  eﬀects	  of	  the	  drinking	  padern	  on	  female	  subjects	  during	  pregnancy	  and	  perinatal	  Jme.	  
To	   this	   aim,	   this	   study	   explored	   the	   consequences	   of	   conJnuous	   vs.	   intermident	   drinking	   padern	   on	  maternal	   behaviour	   and	   on	   oﬀspring	  
vulnerability	  to	  alcohol,	  during	  adulthood.	  	  
Dams	  were	  given	  two-­‐bodle	  choice	  to	  water	  and	  20%	  alcohol	  with	  either	  conJnuous-­‐	  or	  intermident	  access	  (CA	  vs	  IA),	  along	  a	  12-­‐week	  period.	  
They	  suspended	  alcohol	  drinking	  during	  breeding	  and	  resumed	  alcohol	  self-­‐administraJon	  from	  late	  gestaJon	  throughout	  lactaJon,	  when	  they	  
were	  assessed	  for	  home-­‐cage	  undisturbed	  maternal	  behaviour.	  In	  the	  adulthood,	  alcohol-­‐exposed	  oﬀspring	  were	  assessed	  for	  alcohol	  drinking	  
behaviour	  in	  a	  free-­‐choice	  paradigm	  and	  tested	  for	  the	  deprivaJon	  eﬀect.	  
Our	  results	  show	  that	  alcohol	  consumpJon	  and	  preference	  signiﬁcantly	  decreased	   in	   IA	  group	  during	  pregnancy,	  returning	  to	  baseline	  during	  
lactaJon.	  Alcohol	  drinking	  was	  able	  to	  disrupt	  spontaneous	  maternal	  behaviour,	  especially	  in	  IA	  exposed	  dams.	  On	  the	  other	  hand,	  perinatal	  CA	  
exposure	  did	  not	  increase	  alcohol-­‐drinking	  behaviour	  in	  the	  oﬀspring	  with	  respect	  to	  controls,	  while	  rats	  perinatally	  exposed	  to	  IA	  displayed	  a	  
high	  vulnerability	  to	  alcohol,	  in	  terms	  of	  drinking	  behaviour	  and	  deprivaJon	  eﬀect.	  
In	  conclusion,	  this	  study	  indicates	  for	  the	  ﬁrst	  Jme	  that	  the	  padern	  of	  alcohol	  consumpJon	  can	  be	  responsible	  for	  diﬀerent	  extents	  of	  maternal	  
behaviour	  disrupJon	  and	  detrimental	  consequences	  in	  the	  oﬀspring.	  Therefore	  gender-­‐	  but	  also	  padern-­‐related	  diﬀerences	  should	  be	  taken	  into	  
account	  for	  contrasJng	  alcohol	  abuse	  and	  dependence,	  especially	  during	  perinatal	  Jme.	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Repeated	  cocaine	  treatment	  during	  adolescence	  reduces	  spine	  density	  in	  the	  medial	  prefrontal	  cortex:	  a	  potenBal	  
glucocorBcoid	  receptor-­‐mediated	  mechanism.	  
Caﬃno	  L.,	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ObjecBves:	   AbsJnence	   from	   drugs	   of	   abuse	   may	   cause	   an	   aversive	   emoJonal	   state	   that	   drives	   the	   negaJve	   reinforcement	   of	   addicJon,	  
presumably	   deriving	   from	   dysregulated	   neurochemical	   elements	   in	   the	   brain	   reward	   and	   stress	   systems.	   We	   decided	   to	   invesJgate	   the	  
molecular	  mechanisms	  underlying	  short-­‐	  and	  long-­‐term	  withdrawal	  ager	  prolonged	  exposure	  to	  cocaine	  during	  adolescence.	  
Methods:	  We	  exposed	  adolescent	  male	  rats	  to	  cocaine	  (20mg/kg/day	  subcutaneously)	  from	  post-­‐natal	  day	  (PND)	  28	  to	  PND	  42	  and	  sacriﬁced	  
them	  at	  PND	  45	  or	  90.	  We	  focused	  our	  molecular	  analyses,	  using	  Real	  Time	  PCR	  and	  Western	  blot	  techniques	  as	  well	  as	  morphological	  analyses	  
on	  dendriJc	  spines,	  using	  a	  ﬂuorescent	  dyolisJc	  labeling	  technique,	  on	  the	  medial	  prefrontal	  cortex	  (mPFC),	  a	  brain	  region	  that	  is	  sJll	  developing	  
during	  adolescence.	  	  
Results:	  We	  found	  reduced	  expression	  of	  some	  crucial	  eﬀectors	  of	  the	  signaling	  pathways	  that	  regulate	  spine	  acJn	  network,	  an	  eﬀect	  associated	  
with	   a	   reducJon	   in	   corJcal	   dendriJc	   spine	  density	   and	   an	   enhanced	   formaJon	  of	   ﬁlopodia	   in	   cocaine-­‐exposed	   animals	   sacriﬁced	   at	   PND45.	  
Given	   that	  dendriJc	  spines	  are	  known	  to	  be	  altered	  by	  stress	  exposure,	  we	  hypothesized	   that	  developmental	  exposure	   to	  cocaine	  may	  have	  
altered	  the	  mechanisms	  involved	  in	  stress	  response.	  To	  this	  end,	  we	  analyzed	  the	  glucocorJcoid	  receptor	  (GR)	  system	  and	  found	  increased	  GR	  
transcripJon	  and	  translaJon	  as	  well	  as	  increased	  nuclear	  translocaJon	  of	  GR,	  associated	  with	  the	  reduced	  expression	  of	  the	  GR	  co-­‐chaperone	  
FKBP5	  that,	  under	  physiological	  condiJons,	  keeps	  the	  receptor	  in	  the	  cytoplasm,	  in	  the	  mPFC	  of	  cocaine-­‐exposed	  PND	  45	  animals.	  
Conclusion:	  Based	  on	  our	  results,	  we	  speculate	  that	  short-­‐term	  absJnence	  from	  adolescent	  exposure	  to	  cocaine	  alters	  stress-­‐related	  
mechanisms	  leading	  to	  changes	  in	  dendriJc	  spine	  morphology,	  an	  eﬀect	  that	  may	  contribute	  to	  the	  depressive-­‐like	  behavior	  observed	  in	  early	  
cocaine	  withdrawal.	  These	  ﬁndings	  may	  have	  implicaJons	  for	  elucidaJng	  the	  role	  of	  drug	  abuse	  in	  the	  pathophysiology	  of	  stress-­‐related	  
disorders.	  
2C-­‐B	  and	  25I-­‐NBOMe	  impair	  sensorimotor	  funcBons	  in	  mice	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2C-­‐B	  and	  25I-­‐NBOMe	  are	  phenetylamines	  used	  for	  their	  hallucinogenic	  properJes	  and	  easily	  obtainable	  over	  the	  Internet.	  In	  parJcular.	  2C-­‐B	  (2-­‐
(4-­‐bromo-­‐2,5-­‐dimethoxyphenyl)ethanamine)	  is	  a	  well	  known	  compound	  [1]	  since	  it	  was	  synthesized	  in	  the	  '70s	  by	  Alexander	  Shulgin	  [2]	  while	  
25I-­‐NBOMe	   (2-­‐(4-­‐iodo-­‐2,5-­‐dimethoxyphenyl)-­‐N-­‐[(2-­‐methoxyphenyl)methyl]ethanamine)	   is	   a	   novel	   phenetylamine	   that	   has	   recently	   caused	  
several	  cases	  of	  toxicity	  in	  Europe	  [3,4].	   In	  parJcular,	  25I-­‐NBOMe	  is	  a	  potent	  agonist	  at	  the	  human	  5-­‐HT2A	  receptors	  with	  a	  high	  hallucinogen	  
potenJal	   similar	   to	   that	  of	   LSD	   [4].	   In	   fact,	   agonist	   acJvaJon	  of	   5-­‐HT2A	   receptors	   in	   the	   cortex	   is	   believed	   to	  be	   responsible	   for	   remarkable	  
psychopharmacological	   	   eﬀects	   	   exerted	  by	  hallucinogenic	   phenethylamines	   such	   as	   lysergic	   acid	  diethylamide	   (LSD)	   and	  psilocybin	   [5].	   The	  
hallucinatory	   eﬀect	   induced	  by	   phenethylamines	   causes	   a	   profound	   alteraJon	   in	   the	   ability	   to	   perceive	   visual,	   acousJc	   and	   tacJle	   inputs	   in	  
human.	  In	  this	  study,	  we	  invesJgated	  the	  eﬀect	  of	  2C-­‐B	  and	  25I-­‐NBOMe	  administraJon	  on	  sensorimotor	  funcJons	  and	  motor	  coordinaJon	  in	  
CD-­‐1	  male	  mice.	  Eﬀects	   induced	  by	  2C-­‐B	  and	  25I-­‐NBOMe	  administraJon	  were	   invesJgated	  using	  a	  badery	  of	  behavioral	   tests	  widely	  used	   in	  
studies	   of	   "safety-­‐pharmacology"	   for	   the	   preclinical	   characterizaJon	   of	   novel	   molecules	   [6,7].	   In	   parJcular,	   we	   evaluated	   the	   eﬀect	   of	  
compounds	   on	   visual,	   acousJc,	   tacJle	   (pinna,	   vibrissae	   and	   corneal	   reﬂex)	   sensorimotor	   responses	   and	   sJmulated	   motor	   acJvity	   on	   the	  
accelerod	  apparatus.	  The	  eﬀects	  were	  monitored	  up	  to	  300	  minutes	  ager	  drug	  administraJon.	  2C-­‐B	  at	  low	  doses	  (0.01-­‐0.1	  mg/Kg	  i.p.)	  impaired	  
visual	  and	  acousJc	   responses	   in	  mice	  while	  at	  high	  doses	   (1-­‐10	  mg/Kg	   i.p.)	   it	   lost	   these	  eﬀects.	  Whereas	  25I-­‐NBOMe	   (0.0001-­‐10	  mg/Kg	   i.p.)	  
inhibited	  visual	  and	  acousJc	  responses	  up	  to	  10	  mg/Kg	  and	  the	  eﬀects	  extend	  beyond	  5	  hours	  of	  observaJon.	  In	  parJcular,	  25I-­‐NBOMe	  inhibited	  
more	  readily	  and	  with	  greater	  eﬀecJveness	  than	  2C-­‐B	  auditory	  responses	  in	  mice.	  25I-­‐NBOMe	  (0.0001-­‐10	  mg/Kg	  i.p.)	  was	  ineﬀecJve	  in	  altering	  
sensorimotor	   responses	   to	   tacJle	   sJmulaJon	   of	   pinna,	   vibrissae	   and	   cornea.	   While	   2C-­‐B	   (1-­‐10	   mg/Kg	   i.p.)	   transiently	   reduced	   only	   pinna	  
responses.	  Both	  phenethylamines	  did	  not	  aﬀect	  sJmulated	  locomoJon	  on	  the	  accelerod.	  For	  the	  ﬁrst	  Jme	  these	  data	  demonstrate	  that	  2C-­‐B	  
and	   25I-­‐NBOMe	   deeply	   impair	   visual	   and	   acousJc	   sensorimotor	   responses	   in	   mice.	   This	   aspect	   should	   be	   carefully	   evaluated	   to	   beder	  
understand	  the	  potenJal	  danger	  that	  phenethylamines	  may	  cause	  to	  health,	  with	  parJcular	  reference	  to	  performance	  in	  driving	  and	  hazardous	  
works.	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The	  UbiquiBn-­‐26S	  Proteasome	  System	  as	  a	  common	  target	  for	  cocaine	  and	  ethanol	  exposure	  
CapuB,	  Francesca	  Felicia,	  Carboni,	  Lucia,	  Candelep,	  Sanzio	  and	  Romualdi,	  Patrizia.	  
Dept.	  of	  Pharmacy	  and	  Biotechnology,	  Alma	  Mater	  Studiorum	  -­‐	  University	  of	  Bologna,	  Irnerio	  48,	  40126	  Bologna,	  Italy	  
The	   synapJc	   proteins	   proteolysis	   carried	   out	   by	   the	  UbiquiJn-­‐26S	   Proteasome	   System	   (UPS)	   is	   recognized	   as	   a	   criJcal	   component	   in	   neural	  
plasJcity	  [1].	  The	  UPS-­‐mediated	  degradaJon	  system	  plays	  a	  crucial	  role	  in	  synapJc	  remodeling	  and	  in	  memory	  reconsolidaJon	  mechanisms	  ager	  
cocaine	  exposure	  [2].	  Moreover,	  the	  UPS-­‐complex	  is	  involved	  in	  ethanol-­‐induced	  dysfuncJons	  by	  changing	  the	  turnover	  of	  transcripJonal	  factors	  
and	  aﬀecJng	  epigeneJc	  mechanisms	  [3].	  Therefore,	  the	  UPS-­‐complex	  could	  be	  a	  common	  target	  for	  diﬀerent	  drugs	  of	  abuse.	  	  
This	  study	  aimed	  to	  evaluate	  the	  proteolyJc	  proteasome	  acJvity	  and	  the	  gene	  expression	  regulaJon	  of	  speciﬁc	  proteasome	  subunits	  following	  
exposure	   to	  cocaine	  or	  ethanol.	  To	   this	  purpose,	  neuroblastoma	  SHSY-­‐5Y	  cells	  were	   treated	  with	  5µM	  cocaine	  or	  40mM	  ethanol	  at	  diﬀerent	  
Jme	  points:	  2h,	  24h	  and	  48h.	  First	  of	  all,	  an	  opposite	  modulaJon	  by	  cocaine	  and	  ethanol	  was	  observed	  on	  proteasome	  acJvity.	  Indeed,	  while	  
cocaine	   treatment	   increased	   20S	   acJvity	   ager	   2h	   (131±10.63	   vs.	   control	   100±4.54,	   p<0.01),	   ethanol	   exposure	   induced	   an	   acJvity	   reducJon	  
which	  was	  staJsJcally	  signiﬁcant	  ager	  2h	  (86±1.96	  vs.	  control	  100±2.85,	  p<0.05).	  Subsequently,	  we	  analyzed	  the	  mRNA	   levels	  of	  speciﬁc	  26S	  
proteasome	  subunits.	  The	  ß1-­‐ß2	  and	  ß5	  subunits	  belong	  to	  the	  proteasome-­‐20S	  core	  containing	  the	  proteolysis	  acJve	  sites.	  These	  subunits	  were	  
up-­‐regulated	  by	  addicJve	  substance	  treatment.	  Indeed,	  cocaine	  treatment	  increased	  ß1	  gene	  expression	  ager	  2h	  (1.50±0.07	  vs.	  control	  1±0.04,	  
p<0.001)	  and	  ethanol	  exposure	  induced	  similar	  alteraJons	  in	  ß1	  and	  ß2	  subunits.	  In	  parJcular	  the	  ß1	  subunit	  gene	  xpression	  was	  up-­‐regulated	  at	  
2	  and	  24h	  (1.59±0.05	  vs.	  control	  1±0.04;	  2.01±0.12	  vs.	  control	  1±0.07,	  p<0.001	  respecJvely);	  ß2	  mRNA	  levels	  increased	  ager	  24h	  (1.28±0.03	  vs.	  
control	  1±0.07,	  p<0.01).	  The	  α	  subunits,	  which	  maintain	  open	  the	  gate	  between	  core	  region	  and	  19S	  parJcle,	  displayed	  a	  diﬀerent	  modulaJon	  
ager	   cocaine	   and	   ethanol	   exposure.	   Cocaine	   induced	   α5	   gene	   expression	   down-­‐regulaJon	   at	   24h	   (0.59±0.05	   vs.	   control	   1±0.04,	   p<0.05),	  
followed	  by	  up-­‐regulaJon	  ager	  48h	  (1.35±0.07	  vs.	  control	  1±0.08,	  p<0.05).	  A	  similar	  trend	  was	  observed	  for	  α6	  mRNA	  levels,	  which	  were	  down-­‐
regulated	   ager	   2h	   and	   24h	   (0.41±0.05	   vs.	   control	   1±0.06;	   0.38±0.04	   vs.	   control	   1±0.06,	   p<0.001,	   respecJvely),	   and	   up-­‐regulated	   ager	   48h	  
(1.38±0.04	  vs	  control	  1±0.08,	  p<0.001).	  In	  contrast,	  ethanol	  increased	  α5	  gene	  expression	  ager	  2h	  (1.55±0.11	  vs.	  control	  1±0.07,	  p<0.001)	  and	  
48h	  (1.49±0.15	  vs.	  control	  1±0.08,	  p<0.01);	  no	  change	  of	  α6	  mRNA	  was	  observed.	  Concerning	  the	  subunits	  located	  in	  the	  19S	  regulatory	  parJcle,	  
we	   observed	   that	   the	   Rpt3	   subunit,	   involved	   in	   the	  mechanism	   of	   complex	   assembly,	   was	   strongly	   up-­‐regulated	   by	   cocaine	   at	   2h	   and	   24h	  
(1.48±0.06	   vs.	   control	   1±0.05;	   3.87±0.07	   vs.	   control	   1±0.06,	   p<0.001,	   respecJvely).	   Conversely,	   ethanol	   exposure	   induced	   a	   marked	   down-­‐
regulaJon	  ager	  2h	   (0.59±0.09	  vs.	   control	  1±0.05,	  p<0.01).	  Rpn9	  mRNA	   levels	  were	  not	  altered	  by	  cocaine	  or	  ethanol	   treatment	  at	  any	  Jme-­‐
point.	   In	   conclusion,	   our	   data	   showed	   that	   cocaine	   and	   ethanol	   exposures	   aﬀect	   UPS	   acJvity	   and	   gene	   expression	   thus	   strengthening	   the	  
hypothesis	   that	   these	  two	  addicJve	  drugs,	  despite	  displaying	  diﬀerent	  mechanisms	  of	  acJon,	  may	  share	  the	  26S-­‐proteasome	  machinery	  as	  a	  
common	  molecular	  	  target.	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Possible	  role	  of	  the	  endocannabinoid	  system	  in	  the	  acBvity-­‐based	  model	  of	  anorexia	  nervosa	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Anorexia	   Nervosa	   (AN)	   is	   a	   psychiatric	   pathology	   characterized	   by	   excessive	   body	   weight	   loss	   in	   most	   cases	   accompanied	   by	   physical	  
hyperacJvity	  diﬃcult	   to	  control.	  Brain	   imaging	  studies	  have	  shown	  both	  neuroanatomical	  abnormaliJes	  and	  dysfuncJonal	  acJvaJon	  of	  brain	  
areas	  modulaJng	  reward	  in	  AN	  paJents	  (Kaye	  et	  al.,	  2009;	  KeaJng	  et	  al.,	  2012;	  Holsen	  et	  al.,	  2012).The	  endocannabinoid	  system	  (ECs)	  has	  been	  
shown	  to	  contribute	  signiﬁcantly	   in	  the	  modulaJon	  of	  the	  hedonic	  aspects	  of	  eaJng	  behaviour	  (Di	  Marzo	  et	  al.,	  2009),	  and	  a	  link	  between	  its	  
dysregulaJon	  and	  AN	  symptoms	  could	  be	  possible	  (Di	  Marzo	  and	  MaJas,	  2005).	  In	  fact,	  plasma	  concentraJons	  of	  the	  endogenous	  cannabinoid	  
anandamide	   (arachidonoylethanolamide,	   AEA)	   were	   found	   signiﬁcantly	   enhanced	   in	   paJents	   with	   AN	   (Monteleone	   et	   al.,	   2005).	   To	   further	  
elucidate	  the	  role	  of	  the	  ECs	  in	  the	  pathophysiology	  of	  AN,	  the	  aim	  of	  our	  study	  was	  to	  invesJgate	  whether	  the	  pharmacological	  modulaJon	  of	  
the	   ECs	   was	   able	   to	   modify	   the	   aberrant	   eaJng	   behavior	   present	   in	   a	   widely	   validated	   rodent	   model	   of	   AN.	   In	   the	   “acJvity-­‐based	  
anorexia”	  (ABA)	  paradigm,	  animals	  subjected	  to	  a	  restricted	  feeding	  schedule	  (two	  cycles	  of	  restricJon	  separated	  by	  a	  period	  of	  recovery)	  and	  
with	  free	  access	  to	  a	  running	  wheel	  show	  paradoxical	  increased	  running	  wheel	  acJvity	  (RWA)	  and	  a	  dramaJc	  weight	  loss.	  Our	  data	  show	  that	  
subchronic	   treatment	   (6	  days	  of	   the	  second	  cycle	  restricJon)	  with	  both	  the	  CB1/CB2	  receptor	  agonist	  Δ9-­‐tetrahydrocannabinol	   (0.5	  and	  0.75	  
mg/kg)	  and	  the	  syntheJc	  CB1	  receptor	  agonist	  CP	  55,940	  (0.03	  and	  0.06	  mg/kg)	  at	  the	  higher	  doses	  tested	  signiﬁcantly	  reduced	  body	  weight	  
loss.	  Moreover,	  each	  dose	  adenuated	  the	  RWA	  and	  produced	  a	  transient	  increase	  in	  food	  intake.	  However,	  subchronic	  treatment	  with	  the	  CB1	  
receptor	  inverse	  agonist/antagonist	  rimonabant	  at	  the	  doses	  tested	  (0.15	  and	  0.3	  mg/kg)	  did	  not	  modify	  either	  body	  weight	  loss	  or	  RWA	  and	  
produced	  a	  decrease	  in	  food	  intake.	  We	  have	  also	  found	  that	  plasma	  levels	  of	  lepJn	  were	  signiﬁcantly	  decreased	  in	  ABA	  animals	  in	  comparison	  
with	  control	  group;	  on	  the	  contrary,	  circulaJng	  levels	  of	  ghrelin	  and	  corJcosterone	  were	  increased.	  No	  eﬀect	  was	  found	  on	  these	  levels	  ager	  
pharmacological	  treatments	  with	  both	  agonists	  and	  antagonists	  tested.	  Taken	  together	  our	  results	  demonstrate	  the	  involvement	  of	  the	  ECs	  in	  
the	  pathophysiology	  of	  AN	  and	   suggest	   that	  pharmacological	   therapies	  based	  on	   the	  modulaJon	  of	   the	  endocannabinoid	   signaling	  might	  be	  
eﬀecJve	  in	  the	  treatment	  of	  AN.	  
	  
Di	  Marzo	  (2009)	  Int	  J	  Obes	  (Lond).	  Jun;33	  Suppl	  2:S18-­‐24.;	  Di	  Marzo	  and	  MaJas	  (2005)	  Nat	  Neurosci.	  May;8(5):585-­‐9.	  ;	  Holsen	  et	  al.	  (2012)	  J	  Psychiatry	  Neurosci.	  Sep;
37(5):322-­‐32.	  ;	  Kaye	  et	  al.	  (2009)	  Nat	  Rev	  Neurosci.	  Aug;10(8):573-­‐84.;	  KeaJng	  et	  al.	  (2012)	  Neuropsychologia.	  Apr;50(5):567-­‐75.;	  Monteleone	  et	  al.	  (2005)	  
Neuropsychopharmacology.	  Jun;30(6):1216-­‐21.	  
	  
Acknowledgements:	  The	  research	  was	  supported	  in	  part	  by	  Regione	  Autonoma	  della	  SardegnaLR7	  2007	  and	  by	  the	  Italian	  Ministry	  of	  University	  and	  ScienJﬁc	  






GeneBc	  and	  environmental	  factors	  inﬂuencing	  spontaneous	  acBvity	  of	  dopamine	  neurons	  in	  Lewis	  and	  Fischer	  rats	  
Marta	  De	  Felice1,	  Miriam	  Melis1,	  CrisJna	  Cadoni2	  
1Division	  of	  Neuroscience	  and	  Clinical	  Pharmacology,	  Department	  of	  Biomedical	  Sciences,	  University	  of	  Cagliari,	  Monserrato,	  Italy;	  
2CNR	  InsHtute	  of	  Neuroscience,	  NaHonal	  Research	  Council,	  Cagliari,	  Italy.	  	  
Substance	  use	  disorder	  is	  a	  psychiatric	  illness,	  which	  depends	  upon	  interacJons	  between	  inherited	  predisposiJons	  and	  environmental	  factors.	  
Diﬀerent	   variables	   ogen	   interact	   in	   the	   expression	   of	   vulnerable	   phenotypes,	   such	   as	   geneJc	   background,	   gender,	   age	   and	   environmental	  
sepngs.	   In	   fact,	   both	   adolescence,	   being	   a	   criJcal	   period	   for	   brain	   maturaJon,	   and	   environmental	   sepngs	   have	   been	   shown	   to	   increase	  
suscepJbility	  to	  drug	  experimentaJon	  and	  abuse.	  AddicJve	  drugs	  share	  the	  property	  to	  acJvate	  the	  mesocorJcolimbic	  dopamine	  (DA)	  system,	  
which	  has	  long	  been	  implicated	  in	  processing	  reward	  and	  reinforcement.	  Such	  a	  system	  originates	  in	  the	  ventral	  tegmental	  area	  (VTA),	  where	  DA	  
neurons	  are	  located,	  and	  projects	  to	  corJcal	  and	  subcorJcal	  structures.	  VTA	  DA	  neurons	  play	  a	  key	  role	  in	  individual	  vulnerability	  to	  drug	  seeking	  
behavior	  (Marinelli	  et	  al.,	  2003,	  Melis	  et	  al.,	  2009,	  Melis	  et	  al.,	  2013,	  Melis	  et	  al.,	  2014).	  Notably,	  dissimilariJes	  in	  drug	  addicJve	  behavior	  have	  
also	  been	  shown	  by	  taking	  advantage	  of	  innate	  diﬀerences	  between	  inbred	  rat	  strains	  for	  their	  geneJc	  components	  of	  vulnerability/resilience	  to	  
addicJon,	  i.e.	  Lewis	  (LEW)	  versus	  Fischer	  (F344)	  rats,	  respecJvely	  (Kosten	  TA,	  Ambrosio	  E.,	  2002).	  	  
The	  present	  invesJgaJon	  was	  sought	  to	  examine	  the	  followings:	  i)	  whether	  or	  not	  VTA	  DA	  cell	  spontaneous	  acJvity	  and	  their	  acute	  response	  to	  
cocaine	   and	   heroin	   diﬀered	   between	   LEW	   and	   F344	   rats;	   ii)	   whether	   or	   not	   a	   chronic	   nicoJne	   exposure	   (0.4	  mg/kg	   s.c.	   for	   5	   days)	   during	  
adolescence	  would	  aﬀect	  VTA	  DA	  cell	  acJvity	  per	  se	  and/or	   to	  act	  as	  a	  gateway	   to	  drug	  abuse	  by	  modifying	  acute	   responses	   to	  cocaine	  and	  
heroin	  in	  LEW	  and	  F344	  rats,	  at	  adulthood.	  
To	   this	  aim,	  extracellular	   single-­‐unit	   recordings	   from	  VTA	  DA	  cells	  were	  performed	   in	  urethane-­‐anestheJzed	  adult	   LEW	  and	  F344	   rats.	  While	  
staJsJcal	  analysis	  revealed	  no	  diﬀerences	  in	  basal	  spontaneous	  acJvity	  of	  VTA	  DA	  cells	  in	  vehicle	  –treated	  rats	  (n=80	  and	  n=74	  cells	  from	  LEW	  
and	  F344	  rats,	   respecJvely),	  some	  parameters	   (i.e.	  number	  of	  spontaneously	  acJve	  cells,	   frequency	  of	  discharge,	  number	  of	  spikes	   in	  bursts,	  
coeﬃcient	   of	   variaJon)	   of	   VTA	   DA	   cell	   acJvity	   diﬀered	   between	   nicoJne	   –treated	   animals	   (n=55	   and	   n=93	   cells	   from	   LEW	   and	   F344	   rats,	  
respecJvely).	  	  
Acute	   cocaine	   (0.25-­‐2	  mg/kg	   i.v.)	   administraJon	   similarly	  and	  dose-­‐dependently	   reduced	   spontaneous	  ﬁring	   rate	  of	  VTA	  DA	  neurons	   in	  both	  
strains	   irrespecJve	   of	   the	   nicoJne	   pre-­‐treatment	   during	   adolescence.	   Notably,	   when	   acutely	   administered,	   heroin	   (0.02-­‐0.32	   mg/kg	   i.v.)	  
produced	  an	  eﬀect	  that	  was	  larger	  in	  F344	  when	  compared	  with	  LEW	  rats	  independently	  from	  nicoJne	  exposure.	  
Overall,	  our	  results	  suggest	  that	  the	  exposure	  to	  nicoJne	  during	  adolescence	  might	  alter	  basal	  electrophysiological	  parameters	  of	  VTA	  DA	  cells,	  





Acute	  eﬀect	  of	  Ketamine	  on	  mTOR	  downstream:	  p70S6K	  and	  rpS6	  expression	  in	  rat	  brain	  area	  related	  to	  depression	  and	  drug	  
addicBon	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Recent	  research	  showed	  that	  a	  single	  infusion	  of	  ketamine	  induced	  a	  rapid	  anJdepressant	  response;	  this	  acute	  eﬀect	  has	  been	  related	  to	  the	  
capacity	  of	   ketamine	   to	   trigger	  molecular	  mechanisms	  of	  neuroplasJcity.	  Ketamine	  binds	   to	   the	  glutamate	  N-­‐methyl-­‐D-­‐asparJc	  acid	   (NMDA)	  
receptor	  and,	  at	   low	  doses	  blocks	  NMDA	  receptors	   located	  on	   inhibitory	  GABAergic	  neurons.	  There	   is	  evidence	   that	  enhanced	  glutamatergic	  
transmission	   through	   to	   AMPA	   and	   NMDA	   receptors	   ager	   ketamine	   treatment	  may	   result	   in	   increased	   of	   mammalian	   target	   of	   rapamycin	  
(mTOR)	  expression.	  mTOR	  is	  a	  protein	  kinase	  involved	  in	  translaJon	  control	  and	  long-­‐lasJng	  synapJc	  plasJcity	  and	  its	  major	  downstream	  eﬀect	  
is	   the	  acJvaJon	  of	  p70	   ribosomal	  S6	  kinase	   (p70S6K).	  Numerous	   studies	   showed	   that	  acute	  ketamine	  dose-­‐dependently	   increase	   rpS6	   in	   rat	  
brain	  areas	  related	  to	  drug	  addicJon	  and	   	  to	   increased	  of	  dopamine	   level.	  Mice	  C57BL/6J	  Wilde-­‐Type	   	  and	  mice	  Knock-­‐Out	  DA-­‐D3	  gene,	  was	  
divided	  in	  three	  groups	  (n=3-­‐4mice/group)	  and	  each	  genotype	  injected	  with	  saline,	  ketamine	  5	  or	  10mg/kg	  IP.	  At	  60	  minutes	  ager	  injecJon,	  mice	  
were	   anestheJzed,	   transcardially	   perfused,	   and	   the	   brain	   was	   collected	   and	   processed	   for	   immunohistochemistry.	   The	   number	   of	   neurons	  
posiJve	  for	  p70S6K	  and	  rpS6	  immunostaining	  were	  analyzed	  from	  brains	  areas	  involved	  in	  the	  control	  of	  mood	  and/or	  involved	  in	  drug	  addicJon	  
as:	  prelimbic	  (PrL)	  and	  infralimbic	  (IL)	  prefrontal	  cortex,	  hippocampal	  (CA1,	  CA2	  and	  CA3),	  basolateral	  amygdala	  (BL),	  nucleus	  accumbens	  core	  
(AcbC)	  and	  shell	  (AcbSh),	  ventral	  tegmental	  area	  (VTA)	  and	  substanJa	  nigra	  (SN).	  A	  main	  ketamine	  treatment	  eﬀect	  on	  p70S6K	  phosphorylaJon	  
was	  observed	   in	   PrL,	   IL,	   AcbSh,	   SN,	   CA1,	   CA3	   and	  BL.	  Genotype	  eﬀect	   on	  p70S6K	  was	   seen	   in	   IL,	   AcbSh,	  AcbC,	  VTA,	   SN	  and	  BL.A	   signiﬁcant	  
Genotype	   x	   Treatment	   interacJon	   was	   observed	   in	   AcbSh,	   AcbC,	   SN,	   CA1,	   CA2,	   CA3	   and	   BL.	   The	  main	   ketamine	   treatment	   eﬀect	   on	   rpS6	  
expression	   was	   seen	   in	   PrL,	   AcbC,	   AcbSh,	   CA2,	   CA3.	   Genotype	   eﬀect	   was	   observed	   in	   CA2,	   BL,	   whereas	   signiﬁcant	   Genotype	   x	   Treatment	  
interacJon	   was	   seen	   in	   PrL,	   CA2,	   VTA,	   SN.	   Our	   study	   showed	   that:	   the	   neuroanatomical	   padern	   of	   ketamine-­‐induced	   p70S6K	   and	   rpS6	  
phosphorylaJon	  did	  not	  overlap,	  and,	  there	  was	  not	  signiﬁcant	  diﬀerences	  in	  rpS6	  phosphorylaJon	  between	  wild-­‐type	  and	  DA-­‐D3	  KO,	  except	  for	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NicoJne,	  a	  potent	  psychosJmulant	  with	  high	  rewarding	  properJes,	  is	  the	  main	  responsible	  of	  the	  addicJve	  properJes	  of	  tobacco	  smoking	  [1].	  
NicoJne	  disconJnuaJon	   leads	   to	  negaJve	  absJnence	  symptoms	  characterized	  by	  somaJc	   (physical)	  and	  aﬀecJve	   (anxiety)	   	   components	   [2].	  
These	  aversive	  withdrawal	  symptoms	  increase	  the	  risk	  of	  relapse	  to	  smoking,	  thus	  therapies	  that	  prevent	  the	  insurgence	  of	  these	  negaJve	  state	  
may	  represent	  valid	  candidates	  for	  smoking	  cessaJon.	  It	  has	  been	  recently	  shown	  in	  our	  laboratory,	  that	  pioglitazone,	  an	  agonist	  of	  peroxisome	  
proliferator-­‐acJvated	  nuclear	  receptor	  (PPARγ),	  decreases	  alcohol	  consumpJon	  and	  adenuates	  the	  expression	  of	  alcohol	  withdrawal	  signs	  [3].	  
Here	  we	   studied	   the	   eﬀect	   of	   pioglitazone	   on	   spontaneous	  withdrawal	   signs	   in	  Wistar	   rats	   following	   7	   days	   of	   nicoJne	   treatment	   through	  
implanted	  transdermal	  nicoJne	  patches	  (5.2	  mg/rat/day).	  The	  eﬀect	  of	  pioglitazone	  (15.0,	  30.0	  mg/kg,	  p.o.)	  on	  somaJc	  and	  aﬀecJve	  withdrawal	  
signs,	  assessed	  16	  hours	  and	  6	  days	  respecJvely,	  ager	  the	   last	  nicoJne	  administraJon.	   In	  addiJon,	  we	  analyzed	  the	  eﬀect	  of	  pioglitazone	  on	  
spontaneous	  nicoJne	  withdrawal	  signs	  in	  condiJonal	  neuronal	  PPARγ	  knock-­‐out	  (KO)	  mice	  and	  their	  wild	  type	  counterparts	  (WT).	  Dependence	  
was	   induced	   by	   injecJng	   nicoJne	   2	   mg/kg	   (s.c),	   4	   Jmes	   per	   day	   for	   8	   consecuJve	   days.	   The	   eﬀect	   of	   pioglitazone	   and	   the	   eﬀect	   of	   the	  
antagonist,	  GW9662	  (5mg/i.p)	  was	  evaluated	  on	  somaJc	  signs	  and	  withdrawal-­‐induced	  anxiety	   	  (20	  hours	  and	  6	  days	  ager	  the	  last	   injecJon).	  
Furthermore,	  in	  order	  to	  elucidate	  the	  brain	  areas	  involved	  in	  these	  eﬀects,	  we	  performed	  a	  Real-­‐Jme	  qPCR	  analysis	  of	  PPARγ	  gene	  expression	  
in	   the	  amygdala,	  hippocampus	  and	  hypothalamus	  of	  nicoJne-­‐treated	  mice	  at	  20	  hours	  and	  6	  days	  of	   	  withdrawal.	   	  The	   results	   showed	   that	  
pioglitazone	  was	  able	   to	  reduce	  the	  total	  absJnence	  score	  of	  somaJc	  symptoms	  and	  nicoJne-­‐induced	  anxiety	   in	   rats.	  Moreover	  pioglitazone	  
decreased	  the	  nicoJne	  withdrawal	  somaJc	  symptoms	  and	  anxiety	  in	  the	  WT	  but	  not	  in	  PPARγ  	  KO	  mice.	  The	  antagonist	  GW9662	  blocked	  the	  
eﬀect	  of	  pioglitazone	  on	  somaJc	  withdrawal	  signs	  and	  reversed	  its	  anxiolyJc	  eﬀect	  in	  the	  WT	  animals,	  conﬁrming	  the	  involvement	  of	  PPARγ	  in	  
the	  eﬀect.	  The	  gene	  expression	  results	  showed	  that	  6	  days	  of	  nicoJne	  withdrawal	  induced	  a	  signiﬁcant	  increase	  of	  PPARγ  mRNA	  levels	  in	  the	  
amygdala	   and	   that	   pioglitazone	   treatment	   alone	   induced	   a	   signiﬁcant	   overexpression	   of	   PPARγ.	   Hippocampal	   PPARγ  mRNA	   levels	   were	  
signiﬁcantly	   increased	   at	   both	  20	  hours	   and	  6	  days	   into	   	   nicoJne	  withdrawal.	   In	   the	  hippocampus,	   as	  well	   as	   in	   the	   amygdala,	   pioglitazone	  
treatment	  caused	  an	   increase	  of	  PPARγ  gene	  expression,	  whereas	  no	  changes	  were	  observed	   in	   the	  hypothalamus.	  The	  results	  of	   this	  study	  
indicate	   that	   the	   amelioraJon	   of	   nicoJne	   withdrawal	   symptoms	   by	   pioglitazone	   engage	   anxiety-­‐related	   neurocircuitries.	   Above	   all,	   these	  
ﬁndings	  demonstrate	  that	  pioglitazone	  treatment	  may	  oﬀer	  a	  new	  pharmacological	  	  approach	  for	  the	  treatment	  of	  nicoJne	  relapse.	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Cannabinoid-­‐mediated	  modulaBon	  of	  hippocampal	  hyperexcitability:	  focus	  on	  the	  interplay	  with	  nitrergic	  system	  in	  diﬀerent	  
rat	  models	  of	  temporal	  lobe	  epilepsy.	  
Gambino1	  G.,	  Rizzo1	  V.,	  Ferraro1	  G.,	  Schiera1	  G.,	  Cannizzaro2	  C.,	  LenJni1	  E.,	  Giammalva1	  R.,	  Sardo1	  P.	  and	  Carlep1	  F.	  
1Department	  of	  Experimental	  Biomedicine	  and	  Clinical	  Neuroscience,	  University	  of	  Palermo,	  Corso	  Tukory	  129,	  Palermo,	  Italy	  
2Department	  of	  Sciences	  for	  Health	  PromoHon	  and	  Mother	  and	  Child	  Care	  “Giuseppe	  D’Alessandro”,	  University	  of	  Palermo,	  V.	  Vespro	  129,	  Palermo,	  Italy	  
Temporal	  lobe	  epilepsy	  (TLE)	  is	  the	  most	  common	  type	  of	  parJal	  complex	  seizure	  in	  adulthood	  [1].	  Within	  the	  framework	  of	  hyperexcitability,	  
growing	  interest	  has	  risen	  on	  the	  impact	  of	  cannabinoids	  on	  the	  control	  of	  paroxysmal	  phenomena	  [2],	  despite	  their	  reputaJon	  as	  psychotropic	  
substances	  with	   addicJve	   properJes	   [3;	   4].	   In	   this	   regard,	   it	  was	   reported	   that	   the	   on-­‐demand	   producJon	   of	   endocannabinoids	   from	  over-­‐
acJvated	  postsynapJc	  cells	   inhibits	  neurotransmider	   release,	  hence	  protecJng	  against	  excitotoxicity	   in	   the	  hippocampus	   [5;	  6].	  Nonetheless,	  
the	  potenJal	  anJconvulsant	  acJon	  of	  cannabinoids	  has	  not	  been	  fully	  addressed.	  Indeed,	  CB-­‐mediated	  eﬀects	  in	  animal	  models	  are	  adributed	  
not	  only	  to	  the	  funcJonal	  involvement	  of	  the	  classical	  CB	  receptors-­‐dependent	  signalling	  [7;	  8],	  but	  also	  to	  the	  interacJon	  with	  further	  synapJc	  
processes	  concerning	  modulatory	  messengers.	  Among	  these,	  nitric	  oxide	  (NO)	  has	  caught	  our	  adenJon	  since	  it	  apparently	  acts	  as	  a	  mediator	  for	  
cannabinoid	   eﬀects	   [9;	   10].	   In	   the	   current	   study,	   we	   focused	   on	   two	   disJnct	   rat	   models	   of	   TLE,	   the	   Maximal	   Dentate	   AcJvaJon	   and	   the	  
Pilocarpine-­‐induced	   acute	   seizures,	   providing	   electrophysiological	   and	   behavioural	   data	   on	   cannabinoid	   and	   nitrergic	   system	   interplay.	   We	  
evaluated	  the	  anJepilepJc	  eﬀects	  of	  WIN	  55,212-­‐2	   (WIN),	  a	  CB	  agonist,	  and	  of	  7-­‐Nitroindazole	   (7NI),	  a	  preferenJal	   inhibitor	  of	  neuronal	  NO	  
synthase	  (nNOS),	  at	  diﬀerent	  doses,	  alone	  and	  in	  combinaJon.	  MDA	  study	  showed	  that	  these	  drugs	  protected	  animals	  from	  electrically-­‐induced	  
epilepJform	  discharges.	  In	  pilocarpine	  model,	  a	  dose-­‐related	  acJvity	  of	  7NI	  and	  WIN:	  a)	  decreased	  the	  behavioural	  scoring,	  used	  to	  describe	  the	  
severity	  of	  chemically-­‐induced	  acute	  seizures;	  b)	  aﬀected	  latency	  of	  the	  onset	  of	  acute	  convulsions;	  c)	  dampened	  mortality	  rate.	  InteresJngly,	  
the	   combinaJon	   of	   the	   treatments	   brought	   to	   light	   that	   individually	   ineﬀecJve	   doses	   of	   WIN	   turn	   into	   eﬀecJve	   when	   nNOS	   acJvity	   is	  
pharmacologically	   inhibited	   in	   both	   experimental	   condiJons.	   Further	   MDA	   studies	   were	   conducted	   with	   a	   view	   to	   explore	   the	   pathway	  
downstream	  NO.	  To	  achieve	  this,	  we	  modulated	  the	  acJvity	  of	  NO-­‐dependent	  soluble	  Guanylate	  cyclase	  (sGC),	  a	  cGMP-­‐synthase	  enzyme,	  which	  
is	   the	  main	   target	   of	  NO	   signalling.	  We	   exploited	  ODQ,	   a	  NO-­‐dependent-­‐sGC	   inhibitor,	   to	   evaluate	   its	   eﬀect	   in	   co-­‐administraJon	  with	  WIN.	  
Results	  obtained	  suggested	  a	  possible	  involvement	  of	  cGMP	  pathway	  in	  the	  crosstalk	  between	  CB	  and	  NO.	  Taken	  all	  these	  into	  consideraJon,	  
our	  ﬁndings	  suggest	  a	  putaJve	  antagonism	  between	  CB-­‐acJvated	  pathway	  and	  NO	  signalling	   in	  the	  context	  of	  neuronal	  hyperexcitability	  and	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Studies	  on	  the	  toxic	  and	  neuroprotecBve	  eﬀects	  of	  cannabinoids	  in	  models	  of	  cerebral	  ischemia	  and	  ischemic	  tolerance	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Cannabinoids	  (CBs)	  are	  implicated	  in	  a	  number	  of	  physiological	  and	  pathological	  mechanisms	  in	  the	  central	  nervous	  system,	  but	  their	  exact	  role	  
in	   post-­‐ischemic	   brain	   injury	   is	   unclear.	   The	   toxic	   and	   neuroprotecJve	   eﬀects	   of	   syntheJc	   and	   endogenous	   CBs	   were	   evaluated	   in	   rat	  
organotypic	  hippocampal	  slices	  exposed	  to	  oxygen-­‐glucose	  deprivaJon	  (OGD)	  and	  in	  gerbils	  subjected	  to	  bilateral	  caroJd	  occlusion	  for	  5	  min.	  
When	  present	   in	   the	   incubaJon	  medium,	   the	   syntheJc	  CB	  agonists	  WIN	  55212-­‐2	  and	  CP	  55940	  and	   the	  CB1	  agonist	  ACEA	  exacerbated	  CA1	  
injury	   induced	   by	   OGD,	  whereas	   the	   CB1	   receptor	   antagonists	   AM	   251	   and	   LY	   320135	  were	   neuroprotecJve.	   AM	   251	   also	   adenuated	   CA1	  
pyramidal	  cell	  death	  in	  gerbils	   in	  vivo.	  The	  endocannabinoid	  2-­‐arachidonoylglycerol	  (2-­‐AG)	  reduced	  OGD	  injury	  in	  hippocampal	  slices,	  whereas	  
anandamide	  (AEA)	  was	  neurotoxic	  at	  the	  same	  concentraJons.	  The	  eﬀects	  of	  WIN	  55212-­‐2,	  AEA	  and	  2-­‐AG	  in	  slices	  were	  all	  dependent	  on	  the	  
acJvaJon	  of	  CB1	  but	  not	  CB2	  receptors,	  except	  for	  the	  toxic	  eﬀects	  of	  AEA	  that	  were	  also	  dependent	  on	  vanilloid	  TRPV1	  receptors.	  Our	  results	  
suggest	   that	   exogenous	  administraJon	  of	  CB1	  agonists	   and	   the	  producJon	  of	   endocannabinoids	   “on	  demand”	  may	  produce	  diﬀerent,	   if	   not	  
opposite,	  eﬀects	  on	  the	  fate	  of	  neurons	  following	  cerebral	  ischemia.	  
We	  then	  studied	  the	  possible	  role	  of	  endocannabinoids	  in	  a	  model	  of	  ischemic	  tolerance,	  an	  endogenous	  neuroprotecJve	  mechanism	  by	  which	  
exposure	   to	   a	   subtoxic	   insult	   results	   in	   resistance	   to	   a	   subsequent	   lethal	   stressor.	   For	   our	   study,	   we	   used	   a	   pharmacological	   model	   of	  
precondiJoning	  by	  exposing	  the	  slices	  to	  sublethal	  concentraJon	  of	  the	  mGluR1/5	  agonist	  (S)-­‐3,5-­‐Dihydroxyphenylglycine	  (DHPG)	  (10	  µM	  for	  30	  
min)	  and	  24	  h	  later,	  to	  excitotoxic	  exposure	  to	  30	  min	  OGD	  or	  to	  10	  µM	  AMPA	  for	  24	  h,	  which	  leads	  to	  selecJve	  injury	  of	  the	  CA1	  subregion	  24	  h	  
later.	  Ager	  precondiJoning,	  we	  observed	  a	  signiﬁcant	  reducJon	  in	  CA1	  damage	  following	  our	  toxic	   insults.	  We	  performed	  whole-­‐cell	  voltage-­‐
clamp	  recordings	  on	  control	  or	  precondiJoned	  CA1	  pyramidal	  neurons	  of	  organotypic	  slices.	  24	  h	  ager	  exposure	  to	  precondiJoning	  doses	  of	  
DHPG,	  AMPA	  induced-­‐currents	  were	  signiﬁcantly	  reduced,	  while	  the	  expression	  of	  the	  postsynapJc	  proteins	  (GluA1,	  NR2A	  and	   	  NR2B	  subunits	  
and	  of	  PSD-­‐95)	  that	  we	  evaluated	  by	  Western	  blot	  analysis	  was	  not	  modifyed.	  To	  clarify	  the	  mechanisms	  whereby	  DHPG	  induces	  tolerance,	  we	  
invesJgated	  the	  involvement	  of	  the	  endocannabinoid	  system.	  Exposure	  of	  slices	  to	  the	  CB1	  antagonist	  AM251	  during	  precondiJoning	  and	  the	  
subsequent	  24	  h	  recovery	  period	  prevented	  the	  development	  of	   tolerance	  to	  AMPA	  toxicity	   induced	  by	  DHPG.	  Accordingly,	  an	   increase	   in	  2-­‐
arachidonoylglycerol	  (2-­‐AG)	  induced	  by	  the	  MAG-­‐lipase	  inhibitor	  URB602,	  but	  not	  in	  anandamide	  by	  the	  FAAH	  inhibitor	  URB597,	  was	  also	  able	  to	  




Adolescent	  exposure	  to	  cocaine	  modulates	  BDNF	  in	  the	  medial	  prefrontal	  cortex	  of	  adult	  rats	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IntroducBon:	   Drug	   addicJon	   is	   a	   chronic,	   relapsing	   brain	   disease	   that	   results	   from	   the	   loss	   of	   control	   over	   drug	   intake,	   moving	   from	   a	  
recreaJonal	  to	  a	  compulsive	  use	  of	  the	  drugs.	  Although	  evidence	  exists	  that	  chronic	  cocaine	  exposure	  at	  adulthood	  is	  associated	  with	  changes	  in	  
neuroìplasJc	  molecules,	  such	  as	  acJvity-­‐regulated	  cytoskeleton-­‐associated	  protein	  (Arc)	  and	  brain	  derived	  neurotrophic	  factor	  (BDNF),	  few	  data	  
exist	   showing	   that	   cocaine	   exposure	   during	   adolescence	   modulates	   brain	   neuroplasJcity.	   It	   is	   well	   established	   that	   adolescents	   are	   more	  
sensiJve	   than	   adults	   to	   drug	   abuse	   suggesJng	   that	   adolescence	   is	   a	   factor	   of	   vulnerability	   for	   drug	   addicJon.	   Nevertheless,	   the	   potenJal	  
associaJon	   between	   early	   onset	   of	   drug	   use	   and	   higher	   rates	   of	   addicJon	   in	   adulthood	   is	   elusive,	   and	   so	   are	   the	   underlying	   molecular	  
mechanisms.	  
Materials	  and	  methods:	  Male	  adolescent	  rats	  were	  exposed	  to	  cocaine	  during	  adolescence	  (20	  mg/kg),	  from	  postnatal	  day	  (PND)	  28	  to	  PND	  42	  
and	  sacriﬁced	  at	  PND	  90.	  The	  molecular	  analyses	  on	  BDNF	  and	  its	  associated	  network	  were	  carried	  out	  using	  Real-­‐Time-­‐PCR	  technique.	  Protein	  
levels	   were	   analyzed	   by	   western	   blot.	   Our	   analyses	   were	   performed	   in	   the	   medial	   prefrontal	   cortex	   (mPFC)	   that	   is	   sJll	   developing	   during	  
adolescence.	  
Results:	  We	   found	   that	   developmental	   exposure	   to	   cocaine	   altered	   transcripJonal	   and	   translaJonal	   mechanisms	   governing	   neurotrophin	  
expression.	  Total	  BDNF	  mRNA	  levels	  were	  enhanced	  in	  the	  mPFC	  of	  PND90	  rats	  exposed	  to	  cocaine	  during	  adolescence,	  an	  eﬀect	  sustained	  by	  
increased	  BDNF	  exon	   IV	   levels	   through	  the	   transcripJon	   factors	  CaRF	  and	  NF-­‐kB.	  Enhanced	  BDNF	  mRNA	   levels	   resulted	   in	  an	   increase	  of	   the	  
precursor	  and	  mature	  forms	  of	  BDNF	  protein,	  paralleld	  by	  a	  reducJon	  of	  several	  miRNAs	  governing	  BDNF	  translaJon.	  Such	  eﬀect	  results	  in	  the	  
acJvaJon	  of	  the	  trkB/AKT	  pathway	  which,	  through	  increased	  S6	  kinase	  phosphorylaJon,	  increases	  Arc	  protein	  levels	  in	  the	  nucleus	  and	  crude	  
synaptosomal	  fracJon.	  The	  invesJgaJon	  of	  the	  molecular	  mechanisms	  underlying	  such	  changes	  revealed	  that	  absJnence	  altered	  the	  inhibitory	  
and	  degradaJve	  pathways	  regulaJng	  Arc	  expression	  via	  changes	  in	  FMR1,	  Ube3a	  and	  GRM5	  mRNA	  levels.	  The	  up-­‐regulaJon	  of	  Arc	  protein	  led,	  
in	   turn,	   to	   reduced	   AMPA	   GluA1	   mRNA	   and	   protein	   levels,	   indicaJng	   a	   widespread	   impact	   of	   absJnence	   on	   several	   markers	   of	   synapJc	  
plasJcity.	  
Conclusion:	   These	   ﬁndings	   points	   to	   BDNF	   and	   Arc/Arg3.1	   as	  molecular	   signatures	   of	   the	   long-­‐term	   absJnence	   from	   repeated	   exposure	   to	  
cocaine	  during	  adolescence.	  Given	  that	  Arc/Arg3.1	  may	  be	  a	  partner	  of	  BDNF	   in	  mediaJng	  such	  adapJve	  changes,	  we	  may	  speculate	  that	  an	  
absJnence-­‐induced	  alteraJon	   in	   the	  pathway	  of	  BDNF	   together	  with	   changes	   in	   the	   inhibitory	   and	  degradaJon	  pathways	   that	   regulate	  Arc/
Arg3.1	   synthesis	   may	   contribute	   to	   the	   incubaJon	   of	   cocaine	   craving,	   casJng	   fresh	   light	   on	   Arc/Arg3.1	   as	   a	   crossroad	   of	   diﬀerent,	   but	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EsJmates	  suggest	  that	  approximately	  40-­‐50%	  of	  those	  who	  experienced	  childhood	  maltreatment	  (CM),	  will	  develop	  substance	  abuse	  problems.	  
CM	  is	  associated	  with	  increased	  severity	  of	  Substance	  Use	  Disorder	  (SUD)	  and	  frequency	  of	  relapse	  to	  drug-­‐seeking	  (RDS)	  ager	  withdrawal	  (1,2).	  
Among	  diﬀerent	  types	  of	  CM,	  exposure	  to	  physical	  abuse	  is	  the	  experience	  that	  has	  the	  highest	  correlaJon	  with	  SUD.	  However,	  the	  molecular	  
and	  neurobiological	  substrates	  engaged	  during	  early	  traumaJc	  events	  and	  mediaJng	  the	  risk	  for	  SUD	  and	  RDS	  are	  poorly	  understood.	  To	  open	  
perspecJve	   on	   new	   therapeuJc	   targets	   and	   prevenJon	   of	   SUD	   and	  RDS,	   a	   deeper	   understanding	   of	   these	   phenomena	   is	   crucially	   required.	  
Within	  this	   framework,	  the	   idenJﬁcaJon	  of	  non-­‐invasive	  biomarkers	  that	  could	  predict	  subject's	  propensity	  to	  develop	  SUD	  ager	  a	  traumaJc	  
childhood	   is	  highly	  warranted	  and	  an	  essenJal	  prerequisite	   to	   the	  development	  of	  eﬀecJve	  prophylacJc/therapeuJc	   strategies.	  Recently	  we	  
have	  established	  a	  mouse	  model	  of	  exposure	  to	  "hosJle”	  social	  environment	  in	  early	  age.	  In	  our	  experiments	  pre-­‐adolescent	  mouse	  pups	  are	  
exposed	  to	  an	  adult	  aggressive	  male	  mouse	  (Early	  Social	  Stress,	  ESS),	  and	  tested	  for	  cocaine	  seeking	  behavior	  in	  adulthood	  by	  condiJoned	  place	  
preference	  (CPP;	  3,4).	  These	  mice	  show	  high	  cocaine-­‐seeking	  behavior	  and	  reinstatement	  to	  cocaine	  seeking	  at	  doses	  ineﬀecJve	  in	  control	  mice.	  
Being	   the	   relapse	   into	   drug	   abuse	   considered	   a	   central	   problem	   in	   the	   treatment	   of	   addicJon	   and	   the	   possibility	   of	   prevenJng	   it	   using	  
measurable	  non-­‐invasive	  biomarkers,	  considered	  a	  major	  clinical	  "advancement",	  we	  concentrated	  our	  studies	  on	  the	  reinstatement	  phenotype	  
of	   ESS	  mice.	  We	   performed	   a	   genome	  wide	   transcriptome	   analysis	   of	   RNAs	   extracted	   from	   Peripheral	   Blood	  Mononuclear	   Cells	   of	   ESS	   and	  
control	  mice	  in	  withdrawal	  from	  cocaine.	  This	  analysis	  revealed	  that	  more	  than	  1000	  transcripts	  were	  up-­‐regulated	  in	  ESS	  group	  compared	  to	  
controls.	   InteresJngly	   the	   Gene	   Ontology/PANTHER	   pathway	   analysis	   revealed	   that	   these	   genes	   were	   enriched	   in	   the	   classes	   of	   blood	  
coagulaJon,	   integrin	   signaling,	   and	  VEGF	   signaling	  pathways.	  A	   increased	  blood	  coagulaJon	  performance	   in	  ESS	  mice	  was	  also	   conﬁrmed	  by	  
Prothrombin	  Jme	  analysis.	  Finally	  we	  administrated	  a	  pharmacological	   treatment	  aimed	  to	  restore	   these	   funcJonal/biological	  aspects	  during	  
cocaine	  withdrawal.	  Surprisingly	  this	  treatment	  was	  able	  not	  only	  to	  improve	  parameters	  of	  the	  peripheral	  vasculature	  but	  it	  also	  rescued	  the	  
increased	  suscepJbility	  of	  the	  ESS	  mice	  to	  reinstate	  cocaine	  seeking.	  
Currently,	  our	  objecJve	  is	  to	  invesJgate	  how	  gene	  expression	  chanqes	  in	  the	  blood	  are	  connected	  with	  the	  brain	  funcJoning	  and	  to	  clarify	  how	  
they	  associated	  with	  the	  propensity	  to	  relapse	  in	  cocaine-­‐absJnent	  individuals.	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The	  novel	  adamantane	  derivaJve	  APICA	  (N-­‐(adamtan-­‐1-­‐yl)-­‐1-­‐pentyl-­‐1H-­‐indole-­‐3-­‐carboxamide)	  was	  recently	  idenJﬁed	  as	  a	  cannabimimeJc	  
indole	  of	  abuse	  (1,	  2).	  Despite	  its	  novel	  structure,	  APICA	  recalls	  cannabimimeJc	  indoles,	  such	  as	  representaJve	  member	  JWH-­‐018.	  The	  emerging	  
abuse	  problem,	  together	  with	  the	  paucity	  of	  informaJon	  about	  the	  bioacJvity	  of	  APICA	  (3)	  emphasize	  the	  need	  for	  further	  evaluaJon	  of	  the	  in	  
vivo	  pharmacology	  of	  this	  novel	  indole-­‐derived	  compound.	  	  In	  the	  present	  study,	  the	  eﬀects	  of	  APICA	  (0	  -­‐	  1	  -­‐	  3	  mg/Kg,	  i.p.)	  were	  tested	  in	  C57BL/
6J	  mice,	  in	  a	  badery	  of	  tests	  that	  are	  sensiJve	  to	  the	  eﬀects	  of	  psychoacJve	  cannabinoids,	  including	  body	  temperature;	  locomotor	  acJvity	  and	  
behavioural	  reacJvity	  in	  the	  open	  ﬁeld	  test;	  nocicepJon	  in	  the	  tail	  ﬂick	  assay;	  motor	  coordinaJon	  in	  the	  acceleraJng	  Rotarod;	  recogniJon	  
memory	  in	  the	  novel	  object	  recogniJon	  test.	  Furthermore,	  the	  highest	  dose	  was	  also	  evaluated	  following	  the	  pre-­‐treatment	  with	  the	  CB1	  
antagonist	  AM251	  (3	  mg/Kg,	  i.p.)	  or	  the	  CB2	  antagonist	  AM630	  (3	  mg/Kg,	  i.p.).	  Our	  results	  show	  that	  APICA	  was	  able	  to	  dose-­‐dependently	  
decrease	  locomotor	  acJvity	  and	  behavioural	  reacJvity	  in	  the	  open	  ﬁeld,	  whereas	  only	  the	  highest	  dose	  was	  able	  to	  induce	  hypothermia,	  
analgesia,	  motor	  ataxia	  and	  recogniJon	  memory	  impairment,	  with	  respect	  to	  vehicle	  (p<0.01;	  p<0.001).	  	  The	  pretreatment	  with	  the	  CB1	  
antagonist	  AM251	  elicited	  an	  increase	  in	  body	  temperature,	  total	  distance	  travelled	  in	  the	  open	  ﬁeld,	  descent	  latency	  in	  the	  Rotarod,	  and	  a	  
decrease	  in	  tail	  ﬂick	  latency	  (p<0.05;	  p<0.01).	  On	  the	  other	  hand,	  pretreatment	  with	  AM630	  did	  not	  induced	  signiﬁcant	  diﬀerences,	  resulJng	  in	  
hypothermia,	  anJnocicepJon	  and	  motor	  ataxia,	  with	  respect	  to	  vehicle.	  This	  study	  supports	  preliminary	  reports	  on	  APICA	  cannabimimeJc	  
properJes,	  extending	  its	  detrimental	  eﬀects	  on	  cogniJve	  funcJon.	  Moreover,	  these	  properJes	  can	  be	  adributed	  to	  the	  CB1	  receptor	  acJvity,	  
indicaJng	  APICA	  as	  a	  selecJve	  CB1	  receptor	  agonist.	  SelecJve	  CB1	  receptor	  ligands	  may	  be	  useful	  in	  the	  pharmacotherapy	  of	  several	  
pathological	  condiJons;	  nevertheless,	  the	  increased	  use	  as	  designer	  drugs	  of	  abuse	  raises	  signiﬁcant	  public	  health	  concerns.	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  Cannabis	  saJva	  (CS)	  is	  a	  plant	  whose	  use,	  misuse	  and	  abuse	  is	  linked	  to	  the	  various	  possibiliJes,	  recreaJonal	  and	  medical	  too.	  The	  principles	  of	  
Cannabis	  (C)	  	  that	  confer	  pharmacological	  acJvity	  are	  delta-­‐9-­‐tetrahydrocannabinol,	  the	  isomer	  delta-­‐8-­‐tetrahydroccabinol,	  	  tetrahydroccabinol	  
acid,	  cannabinol	  and	  cannabidiol.	  These	  principles	  have	  allowed	  the	  development	  of	  drugs	  that,	  according	  to	  recent	  studies,	  	  may	  replace	  or	  
supplement	  the	  treatment	  of	  many	  diseases,	  especially	  cancer	  and	  neurological	  diseases.	  Alongside	  a	  therapeuJc	  perspecJve	  it	  cannot	  be	  
ignored	  the	  spread	  out	  of	  C	  as	  a	  drug	  of	  abuse,	  raising	  concerns	  on	  its	  medical	  use.	  In	  Italy,	  recent	  naJonal	  legislaJon	  	  started	  in	  2006	  by	  the	  
authorizaJon	  to	  	  import	  drugs	  and	  acJve	  precursors,	  based	  on	  delta-­‐9-­‐tetrahydrocannabinol	  for	  therapeuJc	  purposes,	  in	  the	  absence	  of	  
therapeuJc	  alternaJves,	  in	  paJents	  requiring	  those	  medicines,	  and	  ends	  to	  the	  law	  	  in	  force	  (issued	  January	  23,	  2013),	  which	  sets	  in	  scheduled	  
drugs	  (Table	  2	  sec.	  B	  of	  DPR.309	  /	  1990)	  "herbal	  medicines	  based	  on	  cannabis."	  Lastly	  (September	  2014),	  the	  Health	  Ministries	  and	  Government	  
have	  assigned	  the	  culJvaJon	  and	  producJon	  of	  cannabis	  for	  therapeuJc	  use	  to	  Military	  Chemical	  PharmaceuJcal	  InsJtute.	  	  
In	  our	  contribuJon	  we	  reviewed	  jeopardized	  legal	  paramount	  in	  USA	  about	  medical	  use	  of	  CS	  and	  updated	  medical	  evidence	  about	  pro	  and	  cons	  
to	  CS	  use.	  Since	  2000,	  Colorado	  has	  allowed	  the	  domesJc	  culJvaJon	  of	  C.	  and	  in	  2010	  products	  based	  on	  C.	  were	  admided.	  The	  study	  n	  °	  372/11	  
of	  "the	  New	  England	  Journal"	  published	  March	  12,	  2015	  shows	  that	  the	  number	  of	  consumers	  grew	  from	  4819	  in	  2008	  to	  115,467	  in	  2014.	  This	  
increase,	  in	  associaJon	  with	  authorizaJon	  of	  trading	  substances	  containing	  marijuana	  for	  recreaJonal	  purposes,	  has	  required	  a	  careful	  analysis	  
of	  the	  adverse	  eﬀects	  of	  C.	  	  
This	  study	  provides	  a	  comparaJve	  analysis	  among	  diﬀerent	  regulaJons,	  helping	  in	  evidencing	  criJcality	  and	  advantages	  on	  its	  use	  as	  a	  
therapeuJcal	  alternaJve.	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  nandrolone	  decanoate	  aMenuates	  cocaine-­‐induced	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As	  reported	  by	  the	  World	  AnJ-­‐Doping	  Agency,	  nandrolone	  decanoate	  is	  one	  of	  the	  most	  used	  prohibited	  anabolic	  steroid	  in	  all	  sports	  and	  ogen	  
it	  suse	  is	  associated	  with	  the	  consumpJon	  of	  other	  drugs	  of	  abuse	  such	  as	  cocaine	  (World	  AnH-­‐Doping	  Agency,	  2011;DuRant	  et	  al.	  1995).	  Pre-­‐
exposure	  to	  nandrolone	  has	  been	  demonstrated	  to	  induce	  long	  lasJng	  changes	  in	  neurochemical	  and	  behavioral	  response	  to	  cocaine	  in	  rats.	  For	  
example,	  nandrolone	  inhibited	  cocaine-­‐evoked	  dopamine	  release	  in	  the	  nucleus	  accumbens	  shell,	  a	  neurobiological	  marker	  of	  most	  drugs	  abuse	  
by	  humans	  (Kurlinget	  al	  2005).	  Moreover,	  stereotyped	  behavior	  and	  locomotor	  acJvity	  evoked	  by	  cocaine	  administraJon	  were	  adenuated	  by	  
pre-­‐treatment	   with	   nandrolone	   (Kailanto	   et	   al.	   2011).Similar	   to	   other	   drugs	   of	   abuse,	   in	   animals	   studies	   cocaine	   can	   produce	   reward	   as	  
measured	  by	  behavioral	  reinforcement	  test	  such	  as	  condiJoned	  place	  preference	  (CPP)	  (Spyraki	  et	  al.	  1982),	  a	  procedure	  widely	  used	  in	  rodents	  
to	  assess	  drug	  eﬀects	  related	  to	  reward	  or	  aversion,	  that	  can	  be	  used	  to	  explore	  moJvaJonal	  brain	  reward	  processes	  related	  to	  drugs	  abused	  by	  
humans	  (Tzschentke,	  1998).Using	  the	  CPP	  paradigm,	  the	  aim	  of	  this	  study	  was	  to	   invesJgate	  whether	  pre-­‐exposure	  to	  nandrolone	  decanoate	  
modulates	   the	   rewarding	  eﬀects	  of	  cocaine	   in	   rats.	  We	   found	   that	   intramuscular	   (i.m.)	   injecJon	  of	  nandrolone	  decanoate	   (15mg/kg)	  given	  1	  
hour	   before	   starJng	   cocaine	   condiJoning	   sessions,	   blocked	   the	   development	   of	   CPP	   induced	   by	   cocaine	   (10mg/kg	   i.p.).When	   given	   alone,	  
nandrolone	  did	  not	  produce	  condiJoned	  place	  preference	  or	  place	  aversion.	  Moreover,	  the	  expression	  of	  cocaine	  induce-­‐CPP	  was	  adenuated	  
when	   nandrolone	   decanoate	   was	   given	   daily	   for	   14	   days	   (15mg/kg,	   i.m.)	   before	   starJng	   place	   condiJoning.	   Our	   data	   showed	   that	  
nandrolonedecanoate	  decreased	  the	  rewarding	  eﬀects	  of	  cocaine	  and	  suggest	  that	  chronic	  administraJon	  of	  this	  drug	  may	  induces	  dysfuncJon	  







AlteraBons	  in	  the	  emoBonal	  regulaBon	  process	  in	  gambling	  addicBon:	  	  the	  role	  of	  anger	  and	  alexithymia	  
1,	  2Maniaci	  G,	  3Picone	  F,	  4Dimarco	  T,	  1,2	  Brancato	  A	  and	  1Cannizzaro	  C	  
1Department	  of	  Sciences	  for	  Health	  PromoHon	  and	  Mother	  and	  Child	  Care,	  University	  of	  Palermo	  
2BioNeC,	  University	  of	  Palermo;	  3UOS	  Sert	  Montelepre,	  ASP	  Palermo;	  4UOC	  Dipendenze	  Patologiche,	  ASP	  Palermo	  
Pathological	  Gambling	  is	  conceptualized	  as	  a	  behavioural	  addicJon	  because	  of	  its	  neurobiologic,	  neurophysiologic	  and	  psychological	  features	  
(American	  Psychiatric	  AssociaJon,	  2013;	  Goudriaan	  et	  al.,	  2004;	  Petry	  et	  al.,	  2013).This	  study	  is	  aimed	  at	  the	  assessment	  of	  alexithymia	  and	  
anger	  levels	  in	  100	  treatment-­‐seeking	  pathological	  gamblers	  (PGs)	  compared	  with	  100	  healthy	  controls	  (HCs),	  matched	  for	  age,	  gender	  and	  
educaJon.	  Furthermore	  we	  aimed	  at	  evidencing	  a	  posiJve	  correlaJon	  between	  alexithymia,	  anger	  and	  severity	  of	  gambling	  disorder	  and	  
showing	  a	  relaJonship	  between	  gambling	  behaviour	  and	  anger,	  ager	  controlling	  for	  alexithymia.	  Finally	  the	  fourth	  aim	  was	  to	  explore	  the	  role	  
that	  gender	  plays	  in	  anger	  in	  PGs.	  Psychological	  assessment	  included	  the	  South	  Oaks	  Gambling	  Screen	  (SOGS),	  State-­‐Trait	  Anger	  Expression	  
Inventory-­‐2	  (STAXI-­‐2)	  and	  Toronto	  Alexithymia	  Scale	  (TAS-­‐20).	  StaJsJcal	  analysis	  on	  the	  results	  shows	  a	  greater	  presence	  of	  anger	  levels	  in	  PGs,	  
together	  with	  alteraJons	  in	  emoJonal	  processing.	  Severity	  of	  gambling	  behaviour	  posiJvely	  correlates	  with	  alexithymia	  scores,	  State-­‐Anger	  and	  
Trait-­‐Anger.	  Moreover,	  a	  signiﬁcant	  contribuJon	  of	  anger	  in	  predicJng	  gambling	  behaviour	  has	  been	  revealed	  ager	  controlling	  for	  alexithymia.	  
In	  conclusion,	  anger	  and	  alexithymia	  must	  be	  regarded	  as	  relevant	  components	  of	  the	  psychodiagnosJc	  assessment	  of	  PGs,	  in	  order	  to	  select	  the	  
best	  therapeuJcal	  strategies,	  to	  prevent	  adempted	  suicide	  and	  to	  reduce	  drop-­‐out	  from	  the	  treatment.	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Eﬀects	  of	  single	  and	  repeated	  N-­‐acetylcysteine	  on	  cue-­‐induced	  nicoBne-­‐seeking	  behavior	  
Moro	  F.,	  Di	  Clemente	  A.,	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  C.M.	  and	  Cervo	  L.	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The	   inability	   of	   smokers	   to	   control	   relapse	   to	   drug-­‐seeking	   behavior	   is	   a	   key	   feature	   of	   nicoJne	   addicJon.	   Although	   pharmacotherapy	   and	  
psychosocial	  support	  can	  help	  smokers	  quit,	  the	  high	  relapse	  rates	  indicate	  a	  high	  unmet	  need	  for	  more	  eﬀecJve	  therapies.	  	  
Recent	  studies	  have	  highlighted	  changes	  in	  glutamate	  (Glu)	  levels	  in	  circuitry	  from	  the	  prefrontal	  cortex	  to	  the	  nucleus	  accumbens	  as	  vital	  in	  the	  
reinstatement	   of	   drug-­‐seeking	   behavior.	   Restoring	   basal	   concentraJons	   of	   extracellular	   Glu,	   thereby	   increasing	   tonic	   acJvaJon	   of	   the	  
presynapJc	  group	  II	  metabotropic	  Glu	  receptors	  (mGluR2/3)	  by	  a	  single	  injecJon	  of	  N-­‐acetylcysteine	  (N-­‐AC)	  prevented	  condiJoned	  cues-­‐induced	  
cocaine-­‐	  and	  heroin-­‐seeking	  behavior	  in	  rats	  ager	  drug	  self-­‐administraJon.	  	  
Although	  nicoJne-­‐associated	  cues	  reinstate	  drug-­‐seeking	  and	  raise	  extracellular	  Glu	  in	  the	  nucleus	  accumbens,	  it	  is	  sJll	  not	  clear	  whether	  N-­‐AC	  
can	  inhibit	  cue-­‐induced	  reinstatement	  in	  absJnent	  rats	  ager	  nicoJne	  self-­‐administraJon.	  It	  is	  also	  not	  clear	  whether	  restoring	  Glu	  homeostasis	  
by	  chronic	  N-­‐AC	  treatment	  can	  enhance	  the	  outcome	  of	  cue-­‐exposure	  therapy	  (CET)	  for	  smoking	  cessaJon.	  	  
To	   gain	   this	   informaJon	   we	   used	   rats	   trained	   to	   associate	   discriminaJve	   sJmuli	   (SDs)	   with	   intravenous	   nicoJne	   or	   oral	   saccharin	   self-­‐
administraJon	  vs.	  no-­‐reward	  in	  two-­‐lever	  operant	  cages.	  Reinforced	  response	  was	  followed	  by	  cue	  signaling	  20-­‐second	  Jme-­‐out	  (CSs).	  
Re-­‐exposure	  to	  nicoJne	  or	  saccharin	  SD+/CS+,	  but	  not	  no-­‐reward	  SD-­‐/CS-­‐,	  revived	  responding	  at	  the	  previously	  reinforced	  lever.	  Acute	  N-­‐AC,	  100	  
mg/kg	  i.p.,	  reduced	  cue-­‐induced	  nicoJne-­‐seeking	  behavior	  without	  modifying	  cue-­‐induced	  saccharin-­‐seeking	  behavior.	  Pre-­‐treatment	  with	  the	  
selecJve	  mGluR2/3	  antagonist	  LY341495,	  1	  mg/kg	  i.p.,	  completely	  prevented	  the	  eﬀect	  of	  N-­‐AC	  on	  nicoJne-­‐seeking	  behavior.	  
When	  N-­‐AC	  was	   given	   chronically	   during	   forced	   absJnence	   or	   in	   combinaJon	  with	   CET,	   only	   in	   the	   lader	   condiJon	  N-­‐AC	   not	   only	   reduced	  
nicoJne-­‐seeking	   when	   biologically	   available	   during	   tesJng,	   but	   induced	   lasJng	   anJ-­‐relapse	   acJvity	   that	   was	   sJll	   present	   two	   weeks	   later.	  	  
Chronic	   treatment	  with	  N-­‐AC,	   100	  mg/kg	   i.p.	   but	   not	   60	  mg/kg,	   during	   14	   days’	   exposure	   to	   nicoJne-­‐associated	   cues	   reduced	   drug-­‐seeking	  
without	  any	  tolerance.	  Chronic	  N-­‐AC	  induced	  long-­‐term	  anJ-­‐relapse	  acJvity	  that	  was	  sJll	  present	  14	  days	  ager	  the	  end	  of	  treatment.	  
These	   results	   support	   and	   extend	   previous	   preclinical	   ﬁndings	   suggesJng	   that	   N-­‐AC	   might	   oﬀer	   a	   therapeuJc	   opportunity	   for	   acute	   cue-­‐
controlled	  nicoJne-­‐seeking	  and	  for	  promoJng	  exJncJon	  of	  nicoJne-­‐cue	  condiJoned	  responding.	  In	  view	  of	  the	  conﬂicJng	  results	  so	  far	  in	  the	  
clinical	  evaluaJon	  of	  N-­‐AC’s	  therapeuJc	  acJvity	  for	  smoking	  cessaJon,	  the	  evidence	  that	  chronic	  N-­‐AC	  enhanced	  the	  outcome	  of	  CET	  could	  have	  






NicoBnic	  α7	  receptor	  acBvaBon	  induces	  NMDA	  receptors	  traﬃcking	  in	  glutamatergic	  terminals	  of	  the	  nucleus	  accumbens	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We	   here	   provide	   funcJonal	   and	   immunocytochemical	   evidence	   supporJng	   the	   co-­‐localizaJon	   and	   funcJonal	   interacJon	   between	   nicoJnic	  
acetylcholine	  receptors(nAChRs)	  and	  N-­‐methyl-­‐D-­‐asparJc	  acid	  receptors	  (NMDARs)	  in	  glutamatergic	  terminals	  of	  the	  nucleus	  accumbens	  (NAc).	  
Immunocytochemical	  studies	  showed	  that	  a	  signiﬁcant	  percentage	  of	  Nac	  terminals	  were	  glutamatergic	  and	  possessed	  GluN1	  and	  a7-­‐containing	  
nAChR.	   A	   short-­‐term	   pre-­‐exposure	   of	   synaptosomes	   to	   nicoJne	   (30	   μM)	   or	   choline	   (1mM)	   caused	   a	   signiﬁcant	   potenJaJon	   of	   the	   100	   μM	  
NMDAevoked	  [3H]D-­‐aspartate	  ([3H]D-­‐Asp)	  oulow,	  which	  was	  prevented	  by	  abungarotoxin	  (100	  nM).	  The	  pre-­‐exposure	  to	  nicoJne	  (100	  μM)	  or	  
choline	  (1	  mM)	  also	  enhanced	  the	  NMDA-­‐induced	  cytosolic	  free	  calcium	  levels,	  as	  measured	  by	  FURA-­‐2	  ﬂuorescence	  imaging	  in	  individual	  NAc	  
terminals,	   an	  eﬀect	  also	  prevented	  by	  a-­‐bungarotoxin.	  Pre-­‐exposure	   to	   the	  a4-­‐nAChR	  agonists	  5IA85380	   (10	  nM)	  or	  RJR2429	   (1	  μM)	  did	  not	  
modify	  NMDAevoked	   ([3H]D-­‐Asp)	   oulow	   and	   calcium	   transients.	   The	  NMDA-­‐evoked	   ([3H]D-­‐Asp)	   overﬂow	  was	   parJally	   antagonized	   by	   the	  
NMDAR	  antagonists	  MK801,	  D-­‐AP5,	  5,7-­‐DCKA	  and	  R(-­‐)CPP	  and	  unaﬀected	  by	  the	  GluN2BNMDAR	  antagonists	  Ro256981	  and	  ifenprodil.	  Notably,	  
pre-­‐treatment	  with	  choline	  increased	  GluN2A	  bioJn-­‐tagged	  proteins.	  In	  conclusion,	  our	  results	  show	  that	  the	  GluN2A-­‐NMDA	  receptor	  funcJon	  
can	  be	   posiJvely	   regulated	   in	  NAc	   terminals	   in	   response	   to	   a	   brief	   incubaJon	  with	   a7	   but	   not	   a4	   nAChRs	   agonists.	   This	  might	   be	   a	   general	  
feature	   in	   diﬀerent	   brain	   areas	   since	   a	   similar	   nAChR-­‐mediated	   bolstering	   of	   NMDA-­‐induced	   ([3H]D-­‐Asp)	   overﬂow	   was	   also	   observed	   in	  
hippocampal	  synaptosomes.	  
Eﬀects	  of	  acute	  administraBon	  of	  JWH-­‐018	  on	  cardiovascular	  funcBons	  in	  mice	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SyntheJc	  carmabinoids	   (SCBs)	  have	  been	  used	  as	   recreaJonal	  drugs	   for	   their	  psychoacJve	  eﬀects	   similar	   to	   those	  produced	  by	  cannabis	   [1].	  
These	  compounds,	  commercially	  known	  as	  K2	  or	  "Spice",	  are	  easily	  purchased	  on	  the	  Internet	  market.	  SCBs	  are	  potent	  cannabinoid	  agonists	  that	  
have	  high	  aﬃnity	   for	  CB1	  and	  CB2	  receptors.	  Many	  recent	   reports	   indicate	   that	  SCBs	  create	  a	  serious	  public	  health	   issue	  due	  to	  medical	  and	  
psychiatric	   toxiciJes	   [2,	  3].	   In	  parJcular,	   seizures,	  hyperreﬂexia,	  myoclonias	  and	  cardiac	   toxicity	  appear	   to	  be	  the	  main	  "atypical"	  side	  eﬀects	  
observed	  in	  emergency	  rooms	  [2,	  3].	  in	  parJcular,	  SCBs	  intake	  induces	  harmful	  eﬀects	  on	  cardiovascular	  system	  such	  as	  palpitaJons,	  chest	  pain,	  
arrhythmias	  and	  myocardial	  infarcJon	  [4].	  The	  aim	  of	  this	  study	  was	  to	  invesJgate	  cardio-­‐respiratory	  and	  –vascular	  alteraJons	  induced	  by	  acute	  
administraJon	  of	  JWH-­‐018	  (0.3-­‐6	  mg/Kg	  i.p.)	  in	  awake	  and	  freely	  moving	  CD-­‐1	  mice.	  The	  detecJon	  of	  heart	  rate,	  breath	  rate,	  arterial	  saturaJon	  
(Sp02)	   and	   pulse	   distenJon,	   was	   provided	   by	   a	   non-­‐	   invasive	   apparatus	   that	   uJlizes	   a	   collar	   with	   an	   infrared	   sensor	   (Mouse	   Ox	   Plus).	   The	  
determinaJon	  of	  blood	  pressure	  was	  carried	  out	  by	  the	  BP	  2000	  that	   is	  a	  computerize	  non-­‐invasive	  tail-­‐cuﬀs	  system.	  JWH-­‐018	  (6	  mg/Kg	   i.p.)	  
induced	  relevant	  long-­‐lasJng	  (up	  to	  5	  hrs)	  cardio-­‐respiratory	  changes	  characterized	  by	  deep	  bradycardia	  (health	  rate	  reducJon	  of	  about	  50	  %)	  
alternated	  with	  episodes	  of	   tachyarrhythmias	  and	   tachycardia.	  Cardiac	  eﬀects	  were	  accompanied	  by	  bradypnea	   (breathing	   rate	   reducJon	  of	  
about	   50	  %),	  mild	   and	   transitory	   reducJon	  both	   in	   Sp02	   (Sp02	   reducJon	  of	   about	   25	  %)	   and	   in	   pulse	  distenJon	   (reducJon	  of	   about	   35	  %).	  
Moreover	   JWH-­‐018	   (6	  mg/Kg	   i.p.)	   increased	   the	   systolic	   blood	   pressure	   (+30	  mm/Hg	   at	   10	  minutes	   ager	   JWH-­‐018	   injecJon)	   and	   its	   eﬀect	  
persisted	  up	  to	  1	  hour.	  JHW-­‐018	  also	   increased	  the	  diastolic	  pressure	  (+20	  mm/Hg	  at	  10	  minutes	  ager	  JWH-­‐018	   injecJon)	  but	  the	  eﬀect	  was	  
transient	  and	  signiﬁcant	  only	   in	  the	  ﬁrst	  20	  min	  ager	  the	  drug	   	   injecJon.	  The	  administraJon	  of	  the	  selecJve	  CB1	  receptor	  antagonist/inverse	  
agonist	  AM	  251	  (6	  mg/Kg	  i.p.)	  completely	  reverted	  cardio-­‐respiratory	  and	  vascular	  changes.	  For	  the	  ﬁrst	  Jme	  the	  present	  data	  reproduced	  in	  the	  
mouse	  model	  the	  "atypical"	  cardiorespiratory	  and	  –vascular	  side	  eﬀects	  induced	  by	  SCBs	  in	  humans	  and	  point	  out	  the	  greater	  cardiac	  toxicity	  
induced	  by	  JWH-­‐018	  [3,	  4,	  5].	  Further	  studies	  will	  be	  performed	  to	  invesJgate	  the	  neural	  mechanisms	  involved	  in	  the	  alteraJons	  caused	  by	  the	  
administraJon	  of	  JWH-­‐018	  in	  mice.	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Receptor-­‐receptors	  funcBonal	  cross-­‐talk:	  new	  evidences	  on	  nicoBne-­‐NMDA	  receptor	  interacBon	  
CrisBna	  Padolecchia,	  Guendalina	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In	  a	  recent	  study	  enJtled	  "Prolonged	  nicoJne	  exposure	  down-­‐regulates	  presynapJc	  N-­‐methyl-­‐D-­‐asparJc	  acid	  (NMDA)	  receptors	  in	  dopaminergic	  
terminals	   of	   the	   rat	   nucleus	   accumbens"	   (Salamone	  et	   al.,	   2014)	  we	  have	   addressed	   the	   topic	   of	   the	   cross-­‐talk	   between	  nicoJnic	   receptors	  
(nAChRs)	  and	  the	  NMDA	  receptors	  present	  on	  the	  same	  neuron.	  Moreover,	  we	  have	  demonstrated	  that	  a	  short	  pretreatment	  of	  dopaminergic	  
nerve	   terminal	   to	   nicoJne	   is	   able	   to	   reduce	   selecJvely	   the	   NMDA	   receptors	   funcJon.	   Now	   we	   start	   with	   a	   new	   project	   focused	   on	   the	  
idenJﬁcaJon	   of	   the	  mechanism	   involved	   in	   the	   nAChRs-­‐NMDARs	   funcJonal	   cross-­‐talk.	  We	   study	   neurotransmider	   release	   from	   rat	   nucleus	  
accumbens	   synaptosomes	   prelabelled	   with	   [3H]Dopamine	   and	   [3H]γ	   amino	   butyric	   acid.	   Preliminary	   results	   show	   that	   diﬀerent	   ionotropic	  
pretreatment	   (α-­‐Amino-­‐3-­‐hydroxy-­‐5-­‐methyl-­‐4-­‐isoxazolepropionic	   acid	   (AMPA)	   100μM,	   and	  Adenosine	   triphosphate	   (ATP)	   100μM	  are	   able	   to	  
mimic	   nicoJne	   in	   the	   funcJonal	   down	   regulaJon	   of	   NMDARs	   modulaJng	   Dopamine	   release.	   Conversely,	   metabotropic	   pretreatment	  
(Oxotremorine	  30μM	  and	  (S)-­‐3,5-­‐Dihydroxyphenylglycine	  (DHPG)	  are	   ineﬀecJve.	  Curiously,	  nicoJne	  pretreatment	  fails	  to	  modify,	   in	  the	  same	  
brain	  area,	  the	  funcJon	  NMDARs	  modulaJng	  GABA	  release.	  Based	  on	  this	  evidences,	  we	  will	  test	  the	  possibility	  that	  NMDARs	  present	  on	  GABA	  
terminals	   are	   pharmacological	   diﬀerent	   from	   NMDARs	   modulaJng	   Dopamine	   release.	   Finally,	   using	   a	   bioJnylaJon	   protocol	   coupled	   with	  
western	  blot	  analysis,	  we	  will	  study	  whether	  the	  AMPA	  and	  ATP	  induced	  funcJonal	  down	  regulaJon	  ofNMDARs	  depend	  on	  the	  modiﬁcaJon	  of	  
glutamatergic	  receptors	  traﬃcking.	  All	  together,	  these	  data	  may	  help	  to	  understand	  the	  mechanisms	  that	  regulate	  the	  NMDRs	  plasJcity.	  
Innate	  and	  ethanol-­‐induced	  diﬀerences	  in	  the	  Extended	  Amygdala	  gene	  expression	  between	  Marchigian	  Sardinian	  alcohol-­‐
preferring	  (msP)	  and	  Wistar	  rats	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Several	  studies	  reported	  that	  alcohol	  preferring	  and	  non-­‐preferring	  animals	  exhibit	  diﬀerences	  in	  gene	  expression	  in	  speciﬁc	  brain	  circuitries	  that	  
may	   be	   decisive	   in	   shaping	   the	   vulnerability	   to	   alcoholism	   [1].	   GeneJcally	   selected	  marchigian	   sardinian	   Preferring	   (msP)	   rats	   show	   natural	  
ethanol	  preference	  and	  high	  sensiJvity	  to	  stress	  together	  with	  anxious	  and	  depressive-­‐like	  symptoms	  that	  ameliorate	  following	  ethanol	  drinking	  
[2].	   Among	   the	   circuitries	   involved	   in	   the	   regulaJon	   of	   stress-­‐induced	   drug-­‐seeking	   behaviour,	   the	   extended	   amygdala,	   comprising	   the	   bed	  
nucleus	  of	  the	  stria	  terminalis	  (BNST),	  the	  central	  nucleus	  of	  the	  amygdala	  (AM)	  and	  the	  shell	  of	  the	  nucleus	  accumbens,	  represent	  a	  criJcal	  site	  
[3].	   In	  view	  of	   the	  crucial	   role	  played	  by	   the	  endogenous	  opioid	   system	   in	  ethanol	   intake	   [4],	   in	   this	   study	  we	  aimed	   to	  evaluate	   innate	  and	  
ethanol-­‐induced	  diﬀerences	   in	  dynorphin	  and	  nocicepJn	  systems	  gene	  expression	  in	  the	  AM	  and	  BNST	  of	  Wistar	  and	  msP	  rats.	  Animals	  (n=6)	  
were	  treated	  with	  chronic	  intermident	  10%	  alcohol	  (v/v)	  in	  a	  two-­‐bodle	  free	  choice	  paradigm;	  ager	  30	  days,	  rats	  were	  sacriﬁced	  and	  then	  AM	  
and	  BNST	  were	  rapidly	  harvested	  and	  frozen.	  	  
Real-­‐Jme	   qPCR	   analysis	   showed	   a	   down-­‐regulaJon	   of	   prodynorphin	   (PDYN)	   mRNA	   level	   ager	   ethanol	   intake	   (0.45±0.09	   vs	   msP	   vehicle	  
0.95±0.11,	  p<0.05;	  two-­‐way	  ANOVA,	  Bonferroni’s	  post-­‐hoc	  test)	  in	  the	  AM	  of	  msP	  rats,	  whereas	  no	  changes	  were	  observed	  in	  the	  BNST.	  A	  higher	  
basal	  κ	  opioid	  receptor	  (KOP)	  gene	  expression	  was	  detected	   in	  the	  msP	  than	   in	  Wistar	  rats	  AM	  (1.26±0.05	  vs	  1.00±0.10,	  p<0.05);	  the	  ethanol	  
intake	   caused	   a	   KOP	   down-­‐regulaJon	   in	   the	  msP	  AM	   (0.65±0.04	   vs	  msP	   vehicle	   1.26±0.05,	   p<0.001)	   and	   an	   up-­‐regulaJon	   in	   the	  msP	   BNST	  
(1.41±0.09	  vs	  msP	   vehicle	   0.88±0.04,	   p<0.001).	  Higher	   pronocicepJn	   (PNOC)	  mRNA	  basal	   levels	  was	  observed	  both	   in	   the	  AM	   (2.33±0.21	  vs	  
1.00±0.20,	   p<0.001)	   and	   in	   the	   BNST	   (1.40±0.06	   vs	   1.00±0.11,	   p<0.05)	   of	   msP	   rats	   compared	   to	   Wistar	   animals.	   Ethanol	   intake	   caused	   a	  
signiﬁcant	  decrease	  of	  PNOC	  mRNA	  in	  both	  the	  invesJgated	  regions	  (AM:	  1.67±0.17	  vs	  msP	  vehicle	  2.33±0.21,	  p<0.05;	  BNST:	  0.94±0.09	  vs	  msP	  
vehicle	  1.40±0.06,	  p<0.01)	  of	  msP	  animals	  only.	  Higher	  basal	  expression	  levels	  of	  nocicepJn/orphanin	  FQ	  receptor	  (NOP)	  mRNA	  were	  observed	  
in	  both	  the	  AM	  and	  the	  BNST	  of	  msP	  vs	  Wistar	  rats	  (AM:	  1.81±0.11	  vs	  1.00±0.07,	  p<0.001;	  BNST:	  1.57±0.09	  vs	  1.00±0.09,	  p<0.001).	  Moreover,	  
ethanol	  induced	  a	  NOP	  mRNA	  down-­‐regulaJon	  in	  the	  msP	  rats	  AM	  (0.65±0.13	  vs	  msP	  vehicle	  1.81±0.11,	  p<0.001)	  and	  an	  up-­‐regulaJon	  in	  the	  
msP	  BNST	  (2.06±0.10	  vs	  msP	  vehicle	  1.57±0.09,	  p<0.01).	  These	  ﬁndings	  suggest	  that,	  in	  the	  extended	  amygdala,	  the	  eﬀect	  of	  ethanol	  is	  totally	  
dependent	  on	  the	  genotype,	  since	  no	  alteraJons	  were	  observed	  for	  both	  systems	  in	  Wistar	  rats	  following	  alcohol	  exposure.	  
In	  conclusion,	  this	  study	   indicates	  that	  PDYN/KOP	  and	  PNOC/NOP	  systems	  contribute	  to	  the	  peculiar	  characterisJc	  of	  msP	  in	  which	  an	  innate	  
preference	  for	  alcohol	  has	  been	  co-­‐segregated	  with	  an	  anxious	  and	  depression-­‐like	  phenotype	  and	  that,	  in	  these	  animals,	  alcohol	  intake	  allows	  
recovery	  from	  negaJve	  mood	  states	  acJng	  through	  opioid	  system.	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  11:339-­‐55;2006;	  [3]Koob,	  Eur	  Neuropsychopharmacol.	  13:442-­‐52;2003;	  






Diﬀerent	  modulaBon	  of	  neuroplasBc	  markers	  in	  the	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  brain	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  acute	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  ketamine	  selfadministraBon	   	  	  
Piva	  Alessandro1,	  Caﬃno	  Lucia*2,	  Di	  Chio	  Marzia*1,	  Giannop	  Giuseppe2,	  Venniro	  Marco1,	  Mup	  Anna1,	  Cheung	  David3,	  Yew	  
David	  T.3,	  Fumagalli	  Fabio2,	  Chiamulera	  CrisJano1	  	  
*equally	  contributed	  	  
1Neuropsychopharmacology	  Lab,	  SecHon	  Pharmacology,	  Dept	  Public	  Health	  &	  Community	  Medicine,	  Univ	  Verona,	  Verona;	  	  2DiparHmento	  di	  
Scienze	  Farmacologiche	  e	  Biomolecolari,	  Università	  degli	  Studi	  di	  Milano,	  Via	  Balzarek	  9,	  20133,	  Milano;	  	  3Chinese	  University	  of	  Hong	  Kong,	  
Hong	  Kong.	  
Ketamine	  was	   shown	   to	   own	   reinforcing	   properJes,	   i.e.	   to	   iniJate	   and	  maintain	   selfadministraJon	   as	  well	   as	   anJ-­‐depressant	   eﬀects	   ager	   a	  
single	  dose.	  Evidence	  exists	  showing	   that	  a	  single	  ketamine	   injecJon	   induced	  neuroadapJve	  changes	   in	  addicJonrelated	  brain	  areas,	   such	  as	  
release	  of	  BDNF	  and	  sJmulaJon	  of	  AKT/mTORC1	  signalling	  cascade,	  both	  involved	  in	  synapJc	  strengthening	  and	  LTP.	  The	  objecJve	  of	  this	  study	  
was	  to	  assess	  the	  expression	  of	  neuroplasJcity	  markers	  such	  as	  zif-­‐268,	  rpS6	  and	  BDNF	  in	  brain	  areas	  related	  to	  addicJon	  and	  mood,	  with	  the	  
aim	  to	  possibly	  discriminate	  between	  the	  reinforcing	  and	  anJdepressant	  ketamine	  dose-­‐regimen	  eﬀects.	  	  
Rats	  were	  daily	   trained	  to	  self-­‐administer	   IV	  ketamine	  S/A	   (group	  12x30)	  or	   to	   receive	  a	  single	  ketamine	  0.5	  mg/kg	   IV	   (group	  1x1)	  or	  vehicle	  
(group	  0x1)	  injecJons.	  At	  endpoint	  of	  the	  12x30	  group	  the	  total	  ketamine	  intake	  was	  191.2	  ±	  82.1	  mg/kg	  IV,	  with	  an	  average	  of	  6.4	  mg/kg	  ±	  2.7	  
mg/kg	  IV	  of	  daily	  intake	  (mean	  ±	  SD).	  Brains	  were	  perfused	  and	  processed	  for	  immunohistochemistry	  against	  zif-­‐268	  and	  rpS6	  in	  prelimbic	  (PRL)	  
and	  infralimbic	  (IL)	  cortex,	  nucleus	  accumbens	  core	  (NACC)	  and	  shell	  (NACS),	  ventral	  tegmental	  area	  (VTA),	  hippocampus	  CA1,	  CA2	  and	  CA3,	  and	  
basolateral	  amygdala	   (BLA).	  The	  BDNF	  protein	   levels	   in	  ventral	  striatum	  (VS)	  and	  hippocampus	   (HP)	  were	  processed	  by	  Western	  blopng	  and	  
analysed	  with	  a	  one-­‐way	  ANOVA	  followed	  by	  Fisher’s	  LSD	  test.	  	  
Zif268	   cell	   counJng	   showed	   a	   signiﬁcant	   main	   eﬀect	   of	   ketamine	   IV	   in	   all	   the	   brain	   areas	   except	   for	   hippocampal	   CA3.	   Tukey’s	   mulJple	  
comparisons,	  showed	  a	  signiﬁcant	  eﬀect	  in	  the	  1x1	  vs.	  0x1	  group	  in	  PRL,	  NACC,	  NACS.	  Group	  12x30	  showed	  a	  signiﬁcant	  increase	  vs.	  0x1	  group	  
in	   all	   brain	   regions	   except	  CA3.	   Pearson’s	  mulJple	   comparison	   showed	   correlaJons	   in	   the	  12x30	   group	  between	  hippocampal	   CA	   areas	   and	  
dopaminergic	  nerve	  terminals	  areas.	  In	  group	  1x1,	  signiﬁcant	  correlaJons	  were	  found	  within	  the	  mesocorJcolimbic	  pathway,	  and	  between	  CA3	  
and	  NAC	  areas.	  	  
For	  rpS6,	  a	  signiﬁcant	  main	  eﬀect	  of	  ketamine	  IV	  was	  seen	  in	  all	  the	  analysed	  brain	  areas.	  Tukey’s	  mulJple	  comparisons	  showed	  a	  signiﬁcant	  
diﬀerence	  in	  1x1	  vs.	  0x1	  group	  in	  all	  brain	  areas,	  with	  higher	  acJvaJon	  of	  rpS6	  in	  the	  vehicle	  group.	  12x30	  group	  showed	  a	  signiﬁcant	  decrease	  
of	  rpS6	  in	  all	  brain	  regions	  except	  for	  CA2	  vs.	  vehicle	  and	  a	  signiﬁcant	  increase	  in	  CA1,	  CA2,	  CA3	  and	  BLA	  vs.	  1x1	  group.	  	  
Mature	  BDNF	  levels	  in	  hippocampus	  showed	  a	  signiﬁcant	  increase	  in	  1x1	  vs.	  0x1	  and	  12x30	  groups,	  and	  a	  signiﬁcant	  decrease	  in	  12x30	  vs.	  0x1	  
group;	  proBDNF	  level	  was	  signiﬁcant	  lower	  in	  1x1	  and	  12x30	  groups	  vs.	  vehicle	  group.	  In	  VS	  conversely,	  we	  observed	  a	  signiﬁcant	  increase	  of	  
proBDNF	  in	  12x30	  vs.	  0x1	  and	  1x1	  groups,	  and	  a	  signiﬁcant	  decrease	  of	  mBDNF	  in	  1x1	  and	  12x30	  groups	  vs.	  vehicle	  group	  level.	  	  
Our	   study	   report	   signiﬁcant	   diﬀerences	   in	   padern	   and	   intensity	   of	   zif268	   and	   rpS6	   expression	   due	   to	   ketamine	   S/A	   vs.	   the	   single	   ketamine	  
injecJon.	   These	   diﬀerences,	   together	   with	   results	   on	   BDNF	   expression	   levels,	   might	   suggest	   a	   clear	   molecular	   discriminaJon	   between	  
reinforcing	  and	  anJdepressant	  dose-­‐regimen	  eﬀects	  of	  ketamine.	  	  	  
Role	  of	  Histone	  H3	  Lysine	  9	  Try-­‐MethylaBon	  in	  the	  development	  of	  the	  depressive/psychoBc-­‐like	  phenotype	  induced	  by	  
adolescent	  THC	  exposure	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We	   recently	   demonstrated	   that	   adolescent	   female	   rats	   treated	  with	   the	   psychoacJve	   ingredient	   of	  marijuana	   delta-­‐9-­‐tetrahydrocannabinol	  
(THC),	  develop	  a	  depressive/psychoJc-­‐like	  phenotype	  in	  adulthood.	  Moreover,	  we	  observed	  that	  adolescent,	  but	  not	  adult,	  THC	  exposure	  leads	  
to	  this	  phenotype,	  suggesJng	  that	  adolescence	  may	  represent	  a	  vulnerable	  period	  for	  the	  psychiatric	  consequences	  of	  THC	  exposure.	  However,	  
the	   neurobiology	   of	   this	   vulnerability	   is	   not	   clear.	   Recently,	   several	   papers	   support	   an	   involvement	   of	   epigeneJc	   mechanisms	   in	   the	  
pathogenesis	  of	  psychiatric	  illnesses.	  In	  line	  with	  this	  data,	  in	  the	  PFC	  of	  THC-­‐treated	  animals	  we	  observed	  increased	  tri-­‐methylaJon	  of	  Lysin9	  on	  
the	  histone	  H3	  (H3K9me3,	  associated	  with	  transcripJonal	  repression)	  2	  hours	  ager	  the	  end	  of	  the	  THC	  treatment.	  Moreover,	  24	  hours	  later,	  this	  
increase	  was	  sJll	  present	  together	  with	   increased	  di-­‐methylaJon	  of	  Lysin9	  and	  acetylaJon	  of	  Lysin14	  on	  histone	  H3	  (H3K9me2	  and	  H3K14Ac,	  
associated	  with	  transcripJonal	  repression	  and	  acJvaJon	  respecJvely)	  and	  these	  alteraJons	  returned	  to	  control	  levels	  ager	  24	  hours.	  In	  contrast,	  
adult	  THC	  exposure	  induced	  only	  an	  increase	  of	  H3K9me3,	  2	  hours	  ager	  the	  last	  THC	  injecJon.	  Therefore,	  these	  biochemical	  data	  conﬁrm	  the	  
major	  vulnerability	  of	  the	  adolescent	  brain.	  
	   Since	   the	   histone	  modiﬁcaJon	  mainly	   disrupted	   by	   the	   adolescent	   THC	   exposure	  was	   the	   H3K9me3,	   the	   goal	   of	   the	   present	   work	  was	   to	  
invesJgate	   the	   enzyme	   responsible	   of	   this	  modiﬁcaJon,	   SUV39H1	   ager	   adolescent	   THC	   exposure,	   by	  Western	   Blot.	   To	   this	   aim,	   adolescent	  
female	  rats	  were	  treated	  with	  increasing	  doses	  of	  THC	  twice	  a	  day	  from	  PND	  35	  to	  45	  and	  the	  analysis	  was	  performed	  in	  the	  PFC	  2,	  24	  and	  48	  
hours	  ager	  the	  last	  THC	  injecJon.	  
	  Two	  and	  24	  hours	  ager	  the	  end	  of	  the	  treatment,	  we	  observed	  a	  signiﬁcant	  increase	  in	  SUV39H1	  protein	  levels	  that	  return	  to	  control	  24	  hours	  
later.	  These	  data	  ﬁt	  well	  with	  the	  increase	  in	  H3K9me3	  observed	  at	  the	  same	  Jme-­‐point.	  
	   In	   order	   to	   understand	   the	   possible	   role	   of	   the	  H3K9me3	   in	   the	   development	   of	   the	   	   depressive/psychoJc-­‐like	   phenotype	   induced	   by	   the	  
adolescent	  THC	  exposure,	  we	  next	  administered	  Chaetocin	  (0.1	  mg/Kg,	  one	  a	  day,	  i.p.),	  a	  selecJve	  inhibitor	  of	  SUV39H1,	  	  during	  the	  adolescent	  
THC	  treatment	  and	  we	  performed	  behavioral	  tests	  at	  PND	  75.	  	  
	  Chaetocin	  administraJon	  signiﬁcantly	  prevented	  the	  cogniJve	  deﬁcit	  induce	  by	  the	  adolescent	  THC	  exposure	  in	  the	  Novel	  Object	  RecogniJon	  
test.	  On	  the	  contrary,	  Chaetocin	  administraJon	  did	  not	  prevent	  social	  deﬁcit	  in	  the	  Social	  InteracJon	  test	  and	  behavioral	  despair	  in	  the	  Forced	  
Swim	  Test.	  	  
	  As	  a	  whole,	  these	  data	  suggest	  that	  pharmacological	  modulaJon	  of	  SUV39H1	  prevents	  cogniJve	  deﬁcits,	  but	  not	  the	  alteraJons	  of	  emoJonal	  
behaviors,	  suggesJng	  that	  the	  increase	  of	  H3K9me3	  might	  play	  a	  role	  in	  the	  development	  of	  some	  signs,	  but	  not	  all,	  of	  the	  depressive/psychoJc	  






Withdrawal	  from	  electronic	  cigareMe	  vapour	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NicoJne	  is	  known	  to	  induce	  physical	  and	  psychic	  dependence.	  Although	  born	  in	  2004,	  the	  electronic	  cigarede	  (e-­‐cigarede)	  recently	  has	  rapidly	  
spread	  worldwide.	  UnJl	  now	  only	   few	  controlled	   toxicological	   studies	  are	  available	  and	  so	   far	  no	   studies	  on	   the	  eﬀect	  of	  e-­‐cigaredes	  at	   the	  
molecular	  and	  behavioral	  levels	  have	  been	  performed.	  On	  this	  basis,	  the	  aim	  of	  our	  study	  was	  to	  invesJgate	  the	  behavioural	  and	  biochemical	  
changes	   induced	   by	   e-­‐cigarede	   in	   comparison	   with	   	   standard	   tobacco	   cigarede,	   during	   exposure	   and	   withdrawal,	   	   using	   an	   innovaJve
	  mouse	  model	  of	  vapour	  or	  smoke	  exposure.	  Balb/c	  male	  mice	  were	  exposed	   in	  groups	  of	  30	  animals	  at	  a	  Jme,	   to	   the	  product	  of	  
vapour	  of	   the	  e-­‐cigarede	   liquid	   (containing	  5.6	  mg	  of	  nicoJne)	  or	   to	   the	   smoke	  of	  7	   standard	  cigaredes	   (Chesterﬁeld	  Red)	  or	   to	  air	   (control	  
group),	  3	  Jmes	  a	  day,	  5	  days	  a	  week	  for	  7	  weeks.	  One	  hour	  ager	  the	  last	  session,	  half	  of	  the	  animals	  were	  sacriﬁced	  for	  neurochemical	  analysis,	  
and	  the	  others	  underwent	  mecamylamine-­‐precipitated	  or	  spontaneous	  withdrawal	  for	  the	  purposes	  of	  behavioral	  analysis.	  
Receptor	  binding	  studies	  showed	  a	  signiﬁcant	  up-­‐regulaJon	  of	  α4β2	  neuronal	  nicoJnic	  acetylcholine	  receptor	  subtype	  in	  diﬀerent	  brain	  areas	  of	  
animals	   exposed	   to	  both	  e-­‐cigarede	  and	   standard	   cigarede	   smoke.	   Similar	   brain	   coJnine	   and	  nicoJne	   concentraJons	   and	   comparable	  urine	  
coJnine	  levels	  were	  found.	  During	  mecamylamine-­‐precipitated	  withdrawal	  there	  was	  a	  decrease	  in	  horizontal	  and	  verJcal	  movements	  and	  the	  
presence	  of	   typical	  withdrawal	   symptoms	   and	   signs	   in	  mice	   exposed	   to	   standard	   cigarede	   smoke	  which	  were	  more	  pronounced	   than	   those	  
elicited	   by	   e-­‐cigarede.	   A	   milder	   withdrawal	   syndrome	   was	   observed	   in	   animals	   exposed	   to	   e-­‐cigarede.	   Spontaneous	   nicoJne	   withdrawal	  
syndrome	   evaluated	   from	   24	   hours	   up	   to	   90	   days	   ager	   exposure	   evidenced	   cogniJve	   impairment	   and	   increased	   anxiety	   in	   both	   groups.	  
Surprisingly,	  e-­‐cigarede	  vapour	  exposure	  elicited	  early	  onset	  of	  depressive-­‐like	  behaviour	  and	  a	  more	  severe	  compulsive	  behaviour. 	  	  	  	  	  	  	  
In	  conclusion,	  although	  e-­‐cigaredes	  are	  rapidly	  gaining	  acceptance	  as	  aid	  for	  smoking	  cessaJon,	  it	  is	  necessary	  to	  consider	  their	  possible	  long-­‐
term	  withdrawal	  eﬀects	  on	  anxiety	  and	  depression.	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Ethanol	   is	   responsible	   for	   the	   eﬀects	   of	   alcoholic	   beverages	  whose	   uncontrolled	   use	   represents	   a	   serious	   risk	   factor	   for	   a	   great	   number	   of	  
diseases	  and	  premature	  deaths.	  However,	  in	  spite	  of	  intense	  research	  on	  the	  mechanisms	  by	  which	  ethanol	  aﬀects	  behaviour	  and	  may	  bring	  to	  
development	   of	   alcoholism,	   an	   enormous	   gap	   has	   yet	   to	   be	   ﬁlled	   in	   order	   to	   provide	   pharmacological	   tools	   that	   may	   interfere	   with	   such	  
mechanisms.	  Furthermore,	  the	  achievement	  of	  such	  task	  is	  made	  parJcularly	  diﬃcult	  by	  the	  complex	  phenomenology	  of	  alcoholism	  as	  well	  as	  
by	   its	   mulJfactorial	   determinants.	   Thus,	   besides	   the	   pharmacological	   approaches	   that	   extend	   from	   the	   use	   of	   disulﬁram,	   naltrexone	   and	  
acamprosate,	  recent	  invesJgaJons	  have	  also	  pointed	  to	  herbal	  remedies	  used	  by	  tradiJonal	  and	  folk	  medicine.	  InteresJngly,	  among	  the	  plants	  
that	  are	  widely	  used	  also	  for	  diﬀerent	  indicaJons,	  Pueraria	  lobata	  (Kudzu),	  Panax	  ginseng	  and	  Salvia	  milJorrhiza,	  have	  been	  reported	  to	  be	  of	  
some	  interest	  and	  have	  been	  invesJgated	  to	  be	  suggested	  as	  possible	  adjuvants	  for	  prevenJon	  and	  treatment	  of	  alcoholism.	  Recent	  evidence	  
has	  shown	  that	  Withania	  somnifera	  Dunal,	  a	  herbal	  remedy	  used	  in	  tradiJonal	  medicine	  for	  its	  anJ-­‐inﬂammatory	  properJes,	  reduces	  ethanol	  
withdrawal-­‐induced	  anxiety,	  potenJates	  ethanol-­‐induced	  anxiolysis	  and	  impairs	  morphine-­‐elicited	  place	  condiJoning.	  As	  an	  extension	  of	  these	  
observaJons,	  aim	  of	  this	  study	  was	  to	  invesJgate	  the	  eﬀects	  of	  Withania	  somnifera	  roots	  extract	  (WSE)	  on	  ethanol-­‐elicited	  place	  condiJoning	  
(both	   preference	   and	   aversion)	   and	   on	   moJvaJon	   for	   drinking	   ethanol	   by	   operant	   self-­‐administraJon	   paradigms.	   To	   this	   end,	   in	   place	  
condiJoning	  experiments	  male	  CD-­‐1	  mice	  underwent	  backward	  (condiJoned	  place	  preference,	  CPP)	  and	  forward	  (condiJoned	  place	  aversion,	  
CPA)	  condiJoning	  and	  the	  eﬀects	  of	  WSE	  (50	  and	  100	  mg/kg)	  were	  evaluated	  on	  acquisiJon	  and	  expression	  of	  ethanol-­‐elicited	  CPP	  and	  CPA.	  In	  
self-­‐administraJon	  experiments	  male	  Wistar	  rats	  were	  trained	  to	  self-­‐administer	  ethanol	  (10%)	  by	  nosepoking	  and	  the	  eﬀects	  of	  WSE	  (25	  and	  75	  
mg/kg)	  were	  evaluated	  on	  acquisiJon	  and	  maintenance	  of	  ethanol	  self-­‐administraJon,	  on	  ethanol	  breakpoint	  under	  a	  progressive-­‐raJo	  schedule	  
of	  reinforcement,	  on	  ethanol	  deprivaJon	  eﬀect	  and	  on	  reinstatement	  of	  seeking	  behaviours.	  The	  results	  of	  these	  experiments	  conﬁrm	  1)	  that	  
under	  appropriate	  experimental	  condiJons,	  ethanol	   is	  able	  to	  elicit	  both	  CPP	  and	  CPA;	  2)	  that	  the	  administraJon	  of	  WSE	  signiﬁcantly	   impairs	  
both	  the	  acquisiJon	  and	  the	  expression	  of	  CPP	  and	  CPA,	  without	  aﬀecJng	  spaJal	  memory,	  as	  determined	  by	  a	  two-­‐trial	  memory	  recogniJon	  
task;	   3)	   that	   WSE	   reduces	   acquisiJon,	   maintenance	   and	   breakpoint	   of	   ethanol	   self-­‐administraJon	   as	   well	   as	   the	   deprivaJon	   eﬀect	   and	  
reinstatement	  of	   ethanol-­‐seeking	  behaviour.	  Although	   further	   studies	   are	  necessary	   to	   invesJgate	   in	  detail	   the	  mechanism(s)	  by	  which	  WSE	  
interferes	  with	  the	  moJvaJonal	  properJes	  of	  ethanol	  and	  aﬀects	  ethanol	  taking	  behaviour,	  that	  these	  results	  provide	  support	  to	  the	  suggesJon	  








Varenicline	  decreases	  nicoBne	  self-­‐administraBon,	  but	  not	  alcohol	  consumpBon	  in	  msP	  rats	  with	  concomitant	  access	  to	  both	  
drugs	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Background:	  Alcohol	  and	  nicoJne	  are	  largely	  co-­‐abused	  (1).	  Environmental	  and	  psychosocial	  factors	  are	  responsible	  for	  the	  strong	  associaJon	  
between	  alcohol	  and	  nicoJne	  addicJon,	  however	  a	  variety	  of	  studies	  have	  also	  demonstrated	  pharmacological	  interacJons	  of	  the	  two	  drugs	  at	  
the	  level	  of	  the	  neuronal	  nicoJnic	  receptors	  (nAChRs).	  
Here	  we	  used	  Marchigian	  Sardinian	  alcohol	  preferring	  (msP)	  rats	  (2)	  to	  study	  whether	  alcohol	  consumpJon	  could	  inﬂuence	  nicoJne	  seeking	  and	  
craving	  and	  vice-­‐versa.	  Then,	  we	   invesJgated	   if	  the	  concomitant	  exposure	  to	  nicoJne	  and	  alcohol	  could	  aﬀect	  the	  well-­‐known	  eﬃcacy	  of	  the	  
selecJve	  a4b2	  nACh	  receptor	  parJal	  agonist	  varenicline	  on	  nicoJne	  and	  alcohol	  consumpJon.	  	  
Methods:	  We	   performed	   two	   diﬀerent	  models	   of	   co-­‐abuse:	   the	   ﬁrst	   one	   consisted	   of	   co-­‐administraJon	   of	   nicoJne	   (30	  mg/kg/0.1	  ml)	   and	  
ethanol	   (10%	   v/v)	   together	   in	   the	   same	  operant	   session	   using	   the	   classic	   Skinner	   boxes	   (3).	   In	   the	   second	   one,	  msP	   rats	  were	   concurrently	  
exposed	   to	   daily	   2-­‐hours	   nicoJne	   sessions,	  while	   being	   given	   unlimited	   access	   to	   ethanol,	   22-­‐hours	   per	   day,	   through	   the	   two	   bodle	   choice	  
paradigm.	  
Results:	  Consistent	  with	  previous	  results,	  we	  found	  that	  a	  history	  of	  alcohol	  drinking	  did	  not	  alter	  the	  moJvaJon	  to	  self-­‐administer	  nicoJne	  as	  
measured	  under	  a	  Progressive	  RaJo	  schedule	  of	  reinforcement.	  As	  expected,	  varenicline	  (0.3,	  1.0	  and	  3.0	  mg/kg)	  signiﬁcantly	  	  decrease	  nicoJne	  
self-­‐administraJon	   in	   msP	   (**p<.01)	   independently	   from	   co-­‐exposure	   to	   alcohol	   or	   not.	   InteresJngly,	   varenicline	   did	   not	   alter	   alcohol	  
consumpJon	  either	  in	  home-­‐cage	  two	  bodle	  choice	  condiJon	  or	  following	  operant	  self-­‐administraJon	  paradigm.	  
These	  results	  conﬁrm	  that	  modulaJon	  of	  a4b2	  nAChRs	  by	  varenicline	  represents	  an	  eﬃcacious	  treatment	  to	  adenuate	  nicoJne	  consumpJon	  and	  
expand	  this	  ﬁnding	  in	  animals	  geneJcally	  selected	  for	  excessive	  alcohol	  drinking.	  On	  the	  other	  hand,	  data	  demonstrate	  that	  this	  drug	  is	  not	  able	  
to	  reduce	  alcohol	   intake	  alone	  as	  well	  as	   in	  the	  presence	  of	  concomitant	  nicoJne.	  This	   lader	  ﬁnding	  do	  not	  support	  the	  use	  of	  varenicline	   in	  
alcohol	   abuse.	   Noteworthy	   mixed	   preclinical	   and	   clinical	   results	   have	   been	   so	   far	   reported	   on	   the	   eﬃcacy	   of	   varenicline	   in	   alcohol	   abuse	  
treatment.	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DA-­‐Phen	  as	  a	  new	  potenBal	  DA-­‐mimeBc	  agent	  for	  treatment	  of	  alcohol	  addicBon:	  preclinical	  in	  vivo	  studies	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Rewarding	   and	   reinforcing	   properJes	   of	   alcohol	   are	   mediated	   by	   acJvaJon	   of	   the	   mesolimbic	   dopaminergic	   system1.	   This	   neurosystem	   is	  
hypofuncJonal	  in	  the	  addicted	  brain,	  even	  beyond	  somaJc	  and	  psychological	  signs	  of	  withdrawal.	  BoosJng	  strategy	  on	  the	  dopaminergic	  tone	  
could	   represent	   a	   valid	   approach	   to	   alcohol	   addicJon	   treatment2.	   The	   eﬀects	   of	   a	   new	   dopamine	   conjugate3	   (2-­‐amino-­‐N-­‐[2-­‐(3,4-­‐dihydroxy-­‐
phenyl)-­‐ethyl]-­‐3-­‐phenyl-­‐propionamide,	   DA-­‐Phen)	   on	   operant	   behaviour	   and	   on	   withdrawal	   behaviour,	   following	   alcohol	   deprivaJon,	   were	  
evaluated.	  The	  concentraJon	  of	  acetaldehyde	  (ACD),	  ethanol's	  ﬁrst	  metabolite,	  as	  an	  indirect	  measure	  of	  the	  possible	  DA-­‐Phen	  modulaJon	  in	  
alcohol	  consumpJon,	  was	  also	  assessed.	  Male	  Wistar	  rats	  were	  tested	  in	  an	  operant	  paradigm,	  made	  by	  diﬀerent	  phases:	  HabituaJon	  (Ethanol	  
5%),	   Training	   (Ethanol	   20%),	   ExJncJon	   and	   DeprivaJon/Relapse	   (3	   cycles).	   Rats	   were	   treated	   with	   DA-­‐Phen	   (0.03	   mmol/kg	   i.p)	   during	  
absJnence,	  or	  during	  relapse.	  Behavioural	  reacJvity	  and	  anxiety-­‐like	  behaviour	  during	  withdrawal	  were	  also	  evaluated.	  At	  the	  end	  of	  described	  
paradigm,	   animals	   were	   sacriﬁced,	   and	   DA-­‐Phen	   distribuJon	   in	   organ	   homogenates	   was	   detected	   and	   quanJﬁed.	   Da-­‐Phen	   promoted	   a	  
reducJon	   in	   alcohol	   intake	   by	   50%	   from	   the	   second	   day	   of	   relapse	   (p<0.001).	   DA-­‐Phen	   administraJon	   was	   also	   able	   to	   induce	   signiﬁcant	  
reducJons	   in	   chronically	   alcohol-­‐treated	   rats	  on	  main	  OF	   (total	   distance	   travelled,	  p<0.001;	  percentage	  of	  Jme	  on	   centre,	   p<0.05)	   and	  EPM	  
parameters	  (percentage	  of	  open	  Jme,	  p<0.001;	  open	  arm	  entries,	  p<0.05;	  and	  head	  dippings,	  p<0.001).	  QuanJtaJve	  Da-­‐Phen	  analysis	  indicated	  
a	   	  distribuJon	   in	  kidneys	   (0.806±0.088	  mg/g),	   spleen	   (0.432±0.035	  mg/g),	  plasma	   (0.223±0.065	  mg/g),	   liver	   (0.138±0.006	  mg/g)	  and	  cerebral	  
region	  (0.101±0.008	  mg/g).	  The	  quanJﬁcaJon	  of	  ACD	  in	  brain	  and	  liver	  homogenates	  of	  ethanol	  drinking	  rats	  showed	  a	  reducJon	  in	  ACD	  levels	  
when	  DA-­‐Phen	  was	  administered	  (25.24±1.30	  mg/g	  in	  the	  brain	  and	  3.20±0.60	  mg/g	  in	  the	  liver),	  with	  respect	  to	  untreated	  subjects	  (30.28±2.80	  
mg/g	   in	   the	   brain	   and	   2.25±0.40	  mg/g	   in	   the	   liver).In	   conclusion,	  DA-­‐Phen	   reduces	   ethanol	   intake,	   likely	   enhancing	   dopaminergic	   tone,	   and	  
reduced	  withdrawal	  behaviour.	  Our	  data	  also	  suggest	  that	  DA-­‐Phen	  is	  able	  to	  produce	  the	  decrease	  of	  ACD	  concentraJon	  in	  both	  brain	  and	  liver,	  
probably	  due	  to	  a	  condensaJon	  between	  ACD	  and	  DA-­‐Phen.	  Further	  studies	  are	  ongoing	  in	  order	  to	  verify	  this	  hypothesis.	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  Craving	  is	  a	  prominent	  feature	  of	  alcohol	  dependence	  and	  frequently	  a	  cause	  of	  relapse.	  Aim	  of	  our	  study	  has	  been	  to	  assess	  the	  eﬃcacy	  of	  
speciﬁc	   anJ-­‐craving	   drugs	   for	   the	   treatment	   of	   a	   cohort	   of	   paJents	   diagnosed	   as	   alcohol-­‐dependent.	   Pharmacotherapy	   has	   been	   chosen	  
according	  to	  the	  typology	  of	  craving,	  which	  was	  idenJﬁed	  by	  the	  three-­‐pathway	  psychobiological	  model	  proposed	  by	  Verheul	  et	  al.,	  [1]:	  relief	  
craving,	   reward	  craving	  and	  obsessive	  craving.	  Currently	  available	  pharmacological	  opJons	  were	  acamprosate,	  nalmefene	  and	  topiramate	  for	  
relief	  craving,	  reward	  craving	  and	  obsessive	  craving,	  respecJvely.	  These	  medicaJons	  have	  been	  used	  as	  an	  adjunct,	  not	  an	  alternaJve,	  to	  the	  
clinic’s	  usual	  psychosocial	  and	  pharmacological	  treatment	  program.	  Sixty	  six	  paJents	  (25	  women	  and	  41	  men)	  recruited	  from	  November	  2013	  to	  
November	  2014	  and	  follow-­‐up	  visits	  to	  assess	  drinking	  status	  at	  1	  and	  3	  months	  ager	  inclusion	  have	  been	  performed.	  PaJents	  were	  divided	  into	  
two	  groups:	  treated	  group	  (n=34)	  who	  underwent	  craving	  evaluaJon	  and	  consequently	  received	  speciﬁc	  pharmacotherapy,	  and	  control	  group	  
(n=32).	  Drops	  out	  were	  n=6	  (17%)	  and	  n=8	  (25%)	  in	  treated	  and	  control	  group,	  respecJvely.	  Craving	  was	  idenJﬁed	  as	  relief	  (n=	  21;	  75%),	  reward	  
(n=	  5;	  17.8%)	  and	  obsessive	  (n=	  2;	  7.2%)	  and	  treated	  with	  acamprosate,	  nalmefene	  and	  topiramate,	  respecJvely.	  During	  the	  observaJon	  period,	  
paJents	  of	  the	  treated	  group	  decreased	  craving	  and	  improve	  the	  Visual	  Analogic	  Scale	  (VAS)	  score	  from	  37.1%	  to	  68%	  and	  Obsessive	  Compulsive	  
Drinking	  Scale	  (OCDS)	  score	  from	  62.7%	  to	  76.5%	  at	  1	  and	  3	  months	  of	  treatment.	  Moreover,	  relapsing	  paJents	  in	  treated	  group	  were	  32%	  (n=9)	  
and	  8.6%	  (n=2)	  at	  1	  and	  3	  month	  comparing	  to	  37.5%	  (n=9)	  and	  33%	  (n=5)	  of	  control	  group	  at	  the	  same	  Jme	  period.	  Furthermore,	  relapsing	  
reducJon	   of	   alcohol	   consumpJon	   (g/day)	   was	   greater	   in	   the	   treated	   group	   (58%)	   compared	   to	   the	   control	   group	   (37.8%)	   thus	   showing	   a	  
signiﬁcant	  increase	  in	  the	  relapse	  severity	  in	  the	  latest.	  	  
In	   conclusion,	   these	   ﬁndings	   suggest	   that	   an	   anJ-­‐craving	   therapy	   based	   on	   a	   psychobiological	   model	   could	   be	   eﬀecJve	   for	   retenJon	   in	  
treatment	  and	  relapse	  prevenJon	  in	  alcohol	  dependence.	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CorBcal	  neuroinﬂammaBon	  contributes	  to	  the	  development	  of	  cogniBve	  deﬁcits	  induced	  by	  adolescent	  thc	  exposure	  in	  rats	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Emerging	  evidence	  suggests	  that	  microglia	  might	  play	  a	  crucial	  role	  in	  brain	  development,	  regulaJng	  synapJc	  maturaJon	  and	  funcJon,	  possibly	  
suggesJng	  that	  deﬁcits	  in	  microglia	  funcJon	  may	  contribute	  to	  synapJc	  abnormaliJes	  seen	  in	  some	  neurodevelopmental	  disorders.	  
In	  the	  present	  study,	  we	  evaluated	  whether	  chronic	  exposure	  to	  delta-­‐9-­‐tetrahydrocannabinol	  (THC)	  during	  adolescence	  could	  have	  long-­‐term	  
consequences	  on	  microglia	  funcJons	  and	  we	  explored	  their	  possible	  contribuJon	  to	  the	  development	  of	  THC-­‐induced	  alteraJons	  in	  mood	  and	  
cogniJon	  in	  adult	  female	  rats.	  
To	  this	  aim,	  chronic	  THC	  (or	  vehicle)	  treatment	  was	  performed	  between	  PND	  35	  to	  45	  and	  we	  examined	  whether	  chronic	  THC	  exposure	  during	  
adolescence	  would	  aﬀect	  microglia	   in	   the	   long-­‐term	   in	  brain	   regions	  expressing	  CB1	   receptors	   and	   involved	   in	   the	  modulaJon	  of	  mood	  and	  
cogniJon.	  
We	   found	   that	   adolescent	   THC	   administraJon	   signiﬁcantly	   increased	   the	   expression	   of	   the	   microglial	   marker,	   Iba1,	   by	   about	   40%	   when	  
compared	  to	  vehicle-­‐treated	  controls,	  speciﬁcally	  in	  the	  PFC	  and	  not	  in	  the	  other	  brain	  areas	  under	  invesJgaJon.	  
The	  observed	  alteraJon	  in	  Iba1	  expression	  was	  associated	  with	  increased	  levels	  of	  pro-­‐inﬂammatory	  mediators,	  that	  is	  TNF-­‐α,	  iNOS,	  COX-­‐2,	  and	  
decreased	  expression	  of	  the	  anJ-­‐inﬂammatory	  cytokine,	  IL-­‐10,	  speciﬁcally	  in	  the	  PFC.	  Furthermore,	  a	  signiﬁcant	  up-­‐regulaJon	  of	  CB2	  receptors	  
was	  observed	  on	  microglia	  cells	  in	  the	  adult	  PFC	  following	  adolescent	  THC	  exposure.	  
These	  data	  suggest	  that	  THC	  administraJon	  during	  adolescence	  produces	  persistent	  molecular	  signs	  of	  corJcal	  neuroinﬂammaJon.	  
In	   order	   to	   assess	   whether	  microglia	   acJvaJon	   could	   play	   a	   role	   in	   determining	   the	   behavioral	   phenotype	   observed	   in	   adult	   THC-­‐exposed	  
animals,	   we	   inhibited	   microglia	   acJvaJon	   by	   co-­‐administering	   Ibudilast,	   a	   non-­‐selecJve	   phosphodiesterase	   inhibitor,	   concomitantly	   to	   THC	  
treatment	  and	  animals	  were	  then	  submided	  to	  behavioral	  tesJng	  in	  adulthood.	  
Intriguingly,	   co-­‐treatment	  with	   Ibudilast	   and	   THC	   during	   adolescence	   prevented	  microglia	   acJvaJon	   in	   the	   PFC	   of	   THC-­‐exposed	   animals,	   as	  
demonstrated	  by	  the	  normalizaJon	  of	  Iba1	  levels	  and	  cytokine	  expression.	  More	  interesJngly,	  Ibudilast	  administraJon	  signiﬁcantly	  adenuated	  
the	  development	  of	  cogniJve	  deﬁcits	  associated	  with	  adolescent	  THC	  exposure,	   thus	  suggesJng	   that	  microglia	  acJvaJon	  could	  contribute	   to	  
determine	  some	  of	  the	  behavioral	  alteraJons	  observed	  in	  adult	  THC-­‐treated	  rats.	  
The	   present	   ﬁndings	   demonstrate	   that	   adolescent	   THC	   administraJon	   is	   associated	   with	   long-­‐term	  microglia	   acJvaJon	   within	   the	   PFC	   and	  
experimental	  evidence	  indicate	  a	  causal	  role	  for	  microglial	  acJvaJon	  in	  the	  development	  of	  THC-­‐induced	  cogniJve	  deﬁcits.	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  placebo	  controlled	  study	  on	  eﬀects	  of	  smokeless	  tobacco	  (snus)	  administraBon	  on	  exercise	  endurance	  and	  on	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in	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IntroducBon	  
A	  proliferaJon	  of	  nicoJne	  use	   in	   the	   sport	   environment	  has	  been	  observed	   in	   recent	   years	  mainly	   as	   smokeless	   tobacco	   (snus,	   SS).	   For	   this	  
reason,	  nicoJne	  has	  been	  listed	  on	  World	  AnJ-­‐doping	  Agency’s	  Monitoring	  Program	  from	  2012	  to	  2015	  in	  order	  to	  detect	  potenJal	  paderns	  of	  
abuse.	   However,	   lidle	   is	   known	   regarding	   SS	   potenJal	   performance-­‐enhancing	   eﬀects,	   especially	   on	   faJgue	   percepJon	   during	   endurance	  
performance	  and	  cogniJve	  tasks.	  The	  aim	  of	  this	  research	  was	  to	  assess	  SS	  eﬀects	  on,	  i),	  exercise	  unJl	  exhausJon,	  and,	  ii),	  on	  the	  Iowa	  Gambling	  
Task	  (IGT)	  test	  for	  decision-­‐making	  processing.	  	  
Methods	  
Study	   1.	   The	   study	  was	   a	   double-­‐blind	   placebo	   controlled	   (SP)	   crossover	   design.	  We	   recruited	   14	  male	   non-­‐smokers.	   Subjects	  were	   studied	  
during	   three	   sessions	   on	   cycle-­‐ergometer:	   experimental	   session	   1	   (Exp1)	   consisted	   on	   an	   incremental	   exercise	   test	   to	   determine	   maximal	  
aerobic	  power	  output	  (Wmax);	  Exp2	  and	  Exp3	  consisted	  in	  exercise	  at	  65%	  Wmax	  unJl	  exhausJon	  in	  SS	  or	  SP	  condiJons.	  During	  the	  Exp2	  and	  
Exp3	  muscle	  and	  cerebral	  oxygenaJon	  by	  means	  of	  NIRS	   (near-­‐infrared	  spectroscopy)	  and	  the	  global	   raJng	  of	  perceived	  exerJon	  (RPE)	  were	  
recorded.	  Before	  and	  ager	  all	  experiments,	  subjects	  were	  administered	  the	  Proﬁle	  of	  Mood	  of	  State	  quesJonnaire	  (POMS)	  and	  tested	  by	  means	  
of	  Transcranial	  MagneJc	  SJmulaJon	  (TMS)	  to	  assess	  changes	  in	  corJco-­‐motor	  excitability	  due	  to	  the	  prolonged	  exercise.	  	  
Study	  2.	  The	  aim	  of	  this	  study	  was	  to	  measure	  the	  eﬀect	  of	  SS	  administraJon	  with	  the	  Iowa	  Gambling	  Task	  (IGT)	  an	  experimental	  test	  to	  study	  
decision-­‐making.	  We	  recruited	  40	  male	  non-­‐smokers.	  Subjects	  were	  randomized	  to	  blindly	  receive	  SS	  or	  SP	  on	  two	  diﬀerent	  days	  according	  to	  a	  
cross-­‐over	  design.	  The	  Proﬁle	  of	  Mood	  of	  State	  quesJonnaire	  (POMS)	  was	  administered	  before	  SS	  or	  SP	  administraJon	  and	  at	  the	  end	  of	  IGT.	  	  
Results	  
Study	  1.	  Time	  to	  exhausJon	  (TTE)	  was	  64.4	  ±	  41.5	  min	  ager	  SS	  and	  51.6	  ±	  17.2	  min	  ager	  SP;	  paired	  Student’s	  t-­‐test	  showed	  a	  not	  signiﬁcant	  
diﬀerence	   (19.2%).	  RPE	   in	   the	  ﬁrst	  30	  minutes	  during	  both	  sessions	  showed	  a	  signiﬁcant	  diﬀerence	  ager	  10	  minutes	   from	  start	  exercise.	  We	  
found	  signiﬁcant	  diﬀerences	  in	  the	  cerebral	  and	  muscular	  Jssues	  oxygenaJon	  levels	  in	  the	  ﬁrst	  30	  minutes	  of	  the	  exercise	  during	  SS	  and	  SP	  tests.	  	  
Study	  2.	  No	  diﬀerences	  were	  observed	  in	  overall	  net	  score	  (SP	  vs.	  SS).	  A	  signiﬁcant	  diﬀerence	  was	  observed	  for	  net	  scores	  in	  T1	  (1-­‐20	  choices)	  
between	   the	   SS	   and	   the	   SP	   condiJon	   (p=0.0499;	   paired	   Student’s	   t-­‐test).	   Twenty-­‐three	   subjects	   reported	   adverse	   events	   at	   the	   end	   of	   SS	  
session.	  	  
Conclusions	  
The	  study	  showed	  that	  the	  SS	  eﬀect,	  compared	  to	  placebo	  condiJon,	  could	  not	  be	  an	  improvement	  of	  faJgue	  during	  an	  endurance	  exercise	  unJl	  
exhausJon	  despite	  of	  an	  increased	  Jssue	  muscular	  and	  cerebral	  oxygenaJon	  (Study	  1).	  It	  seems	  that	  the	  SS	  may	  produces	  an	  early	  but	  transient	  
cogniJve	   improvement	   at	   IGT.	   However,	   adverse	   SS	   eﬀects	   could	   have	   detrimental	   eﬀects	   on	   performance	   in	   naïve	   users	   reducing	   the	  
probability	  of	  the	  doping	  liability	  risk	  (Study	  2).	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